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1 Introduction 
1.1 HPA axis 
In 1922 the American scientist Philip E. Smith was one of the first, who described the 
beneficial clinical effects of adrenocortical extracts in animal models of adrenal 
insufficiency [32]. In the following years, scientists across the globe tried to understand the 
mechanism of action of adrenal hormones and other substances chemically very closely 
related to them. 
Hypothalamic-hypophysiotropic factors were originally proposed by Geoffrey W. Harris in 
the 1940s. Since then substantial achievements, which were highlighted with a Nobel 
Prize 10 years later, confirmed that these factors do indeed exist [26].  
In 1950 the Karolinska Institutet in Stockholm decided to award the Nobel Prize in 
Physiology or Medicine jointly to Dr. Philip S. Hench (1896-1965), Professor Edward C. 
Kendall (1886-1972) and Professor Tadeus Reichstein (1897-1996) ‘for their discoveries 
regarding the hormones of the adrenal cortex, their structure, and biological effects’ [21]. 
Their outstanding achievements through their work on the effect of pituitary 
adrenocorticotropic hormone (ACTH) and cortisol has contributed to open the door to 
new therapeutically concepts for the control of a wide variety of diseases, ranging from 
rheumatoid arthritis to some of the more perplexing cardiovascular and dermatological 
disorders [22].  
Nowadays it should come as no surprise that the hypothalamus is centrally involved in 
orchestrating the appropriate humoral, visceromotor, and somatic motor responses. The 
humoral response is mediated by the hypothalamic-pituitary-adrenal (HPA) axis, which 
plays an important role in maintaining the homeostasis of an organism against stressful 
stimuli [61]. The HPA axis is the major part of the neuroendocrine system and its main role 
is to subserve the body’s response to a stressor, physical or emotional, that disrupts the 
homeostatic balance of the organism [11]. 
The pituitary is composed of a thin intermediate portion (pars intermedia), the anterior 
lobe (adenohypophysis), and a posterior lobe (neurohypophysis). Each has its own 
characteristic endocrine functions.  
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Fig. 1.1: The Hypothalamic-Pituitary-Adrenal Axis (modified from [61]) 
In response to a wide variety of stresses corticotropin releasing hormone (CRH) is 
released from the hypothalamus and stimulates the anterior pituitary to secrete ACTH, 
which in turn stimulates the adrenal cortex to secrete cortisol (Fig. 1.1). The sensitivity of 
the HPA-axis to incoming stimuli is modulated by two negative feedback mechanisms of 
cortisol targeted to the hypothalamus and the anterior pituitary gland. Therefore the 
sequential release of CRH and ACTH is suppressed by the glucocorticoids themselves and 
the magnitude of the HPA stress response depends upon the pre-existing glucocorticoid 
tone [5]. 
The interactions and feedback mechanisms among the involved cell types are highly 
complex and yield central topics of current research in the biomedical field [7][13][18][23] as 
well as in system biology for developing suitable models [55][56][57][58][59]. 
1.1.1 Anterior pituitary gland cell 
Unlike the posterior lobe, which really is a part of the brain, the anterior lobe of the 
pituitary is an actual gland synthesising and secreting a wide range of hormones that 
regulate secretions from other glands throughout the body [61]. The pituitary hormones 
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act on different target organs of the endocrine system: on the gonads, the thyroid glands, 
the adrenal glands, and the mammary glands (Tab.1.1). 













(increases metabolic rate) 
Adenocorticotropic hormone 
(ACTH, corticotropin) 
Adrenal cortex Cortisol secretion  
Growth hormone (GH, 
somatotropin) 
All cells 
Stimulation of protein 
synthesis 
Prolactin Mammary glands Growth and milk secretion 
Tab.1.1: Hormones of the Anterior Pituitary (modified from [61]) 
It should be emphasized that perhaps all of the anterior pituitary hormones are secreted 
by cells elsewhere in the body and may have functions quite different from those in the 
HPA-axis. For example, ACTH is an important neurotransmitter in several brain areas [67]. 
1.1.2 AtT-20 cell line as model system 
An adherent ACTH-producing cell line (AtT-20) derived from a pituitary tumor from an 
irradiated LAF1 mouse 
[41] was chosen as a model secretory system for investigating ACTH 
response to different stress conditions as these cells retain many important biochemical 
and physiological properties similar to human pituitary corticotrophs.  
However, in vitro cell cultures of AtT-20 pituitaries are very sensitive to any kind of stress. 
Already a little divergence in standard temperature (37°C), in vibrations, in lack of space 
to each other, or a pH change as well as too long exposure to light (see Tab.1.2) will 
induce additional (‘unwanted’) stress in AtT-20 cells and thus will have an effect on the 
basal ACTH levels and the significance of the result. 
Since most of these stress factors, such as temperature change, vibrations or exposure to 
light, arise from human mistakes during experimental procedure, lots of unwanted stress 
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can be prevented by gently handling the in vitro culture and by choosing the right cell 
line. The additional risk of vibrations by clashing with other – mostly apoptotic – cells in 
solution is enhanced in AtT-20 suspension cell cultures. Therefore the adherent AtT-20 
cell line was used for all measurements to diminish unwanted influence of this stress 
stimulus to the basal ACTH production during in-vitro analysis.  
Stress stimulus Action 
Temperature 
Optimal growing conditions are guaranteed in an 
incubator at 37°C. Removing cells from the incubator for 
analysis, e.g. for adding stress stimuli or for 
morphological studies, result in a temperature change 
and thus in a stress response.  
vibrations  
Vibrations due to human mistakes in handling result in 
mechanical shear force or clashing with apoptotic cells 
detached from the layer. 
Space 
An increasing cell number in a closed in vitro system 
leads to a lack of space for all cells adhered on the layer. 
As a consequence of the high cell density cells release 
signal molecules into the extracellular space and act 
locally on neighbouring cells causing stress, growth 
arrest and maybe apoptosis in the end.  
pH-value 
Cell growing goes along with increasing degradation 
products which cells accumulate during incubation. 
Without any medium change these waste materials lead 
to an acidic environment for the cells after 4-5 days and 
thus induce stress and apoptosis. 
Light 
As the pituitary gland lies in a pocket of the sphenoid 
bone at the base of the brain, cells remain in the dark all 
the time in vivo and thus a too long exposure to light in 
an in vitro system can result in a stress response. 
Tab.1.2: Additional stress factors for adherent AtT-20 during in-vitro analysis 
Moreover a good experimental setup with fix working steps for each sample preparation 
and measurement minimizes these sources of error and, thus, give rise to a statistically 
relevant basal level of ACTH stimulated by all additional stress factors. Any deviation to 
the basal ACTH level is noticed as a response to any stress factor derived from the HPA 
axis, such as CRH from the hypothalamus or cortisol from the adrenal glands. 
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Nevertheless it has to be pointed out that stress stimuli induced by a lack of space for the 
cells or a pH-change in the medium illustrate the limitation of a closed in vitro system 
after a long incubation period. Both are side effects of the cell growth: As cells undergo 
metabolic processes, acid is produced and the pH decreases. The buffer range of the 
medium is limited, meaning that too acidic levels will result in a dramatic pH decrease in 
the medium monitored as a colour change of the indicator from red to yellow. Secreted 
molecules may act as local mediators, affecting cells in the immediate environment of the 
adhered signalling cells. 
1.1.3 Associated diseases 
Recent research showed evidence that the so-called network diseases, which cannot be 
linked to a single indicator, like Alzheimer‘s disease [34], anxiety disorders [15][38] or 
Cushing‘s syndrome [9] are strongly linked to an abnormal function of the HPA axis.  
Obstructive sleep apnea (OSA) is a common condition with significant cardiovascular and 
metabolic comorbidity and is associated with marked disturbances in ACTH and cortisol 
secretory dynamics, resulting in prolonged tissue exposure to disordered, elevated 
hormone levels [13]. 
There is evidence that the HPA-axis is centrally involved in the linkage between the 
nervous and immune systems [33]. 
Catecholamines, glucocorticoids, ACTH and other stress hormones can modulate the 
activity of multiple components of the tumour microenvironment such as the promotion 
of tumour-cell growth or the stimulation of angiogenesis by inducing production of pro-
angiogenic cytokines [1]. Stress hormones can also activate oncogenic viruses and alter 
several aspects of immune function including antibody production, cytokine production 
profiles (e.g. interleukin-6) and cell trafficking [1]. 
Furthermore the HPA-axis effects and triggers a broad spectrum of diseases, but 
discussing all of them would go beyond the scope of this work. 
1.2 ACTH 
Adrenocorticotropic hormon (ACTH) – often simply referred as corticotrophin or 
adrenocorticotropin in literature – is a 4.5 kDa straight-chain peptide hormone consisting 
of 39 amino acids (Fig. 1.2). It is often produced in response to biological stress – 
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especially under the regulation of CRH from the hypothalamus – by a specialized 
subgroup of pituitary cells, the corticotrophs, which are located in clusters in the pars 
distalis of the pea-sized pituitary gland at the base of the brain. 
Ac – Ser  Tyr  Ser  Met  Glu  His  Phe  Arg  Trp  Gly  Lys  Pro  Val  Gly  Lys  Lys  Arg  Arg  Pro  Val  Lys  Val  Tyr  
Pro  Asn  Gly  Ala  Glu  Asp  Glu  Ser  Ala  Glu  Ala  Phe  Pro  Leu  Glu  Phe – NH2 
Fig. 1.2: ACTH sequence of mouse AtT-20 pituitary gland cells (three-letter-code) 
The properties of ACTH were first investigated in the 1930s by the research groups of 
James Collip, Herbert Evans and Bernardo Houssay using pituitary extracts to stimulate 
the adrenal cortex, but not distinguishing between substances, which are chemically very 
closely related to ACTH, in these extracts. 
1.2.1 Cellular synthesis 
These results suggest that non-genomic and genomic mechanisms are involved in the 
glucocorticoid negative regulation of ACTH expression, and a pertussis toxin-sensitive 
GTP-binding protein might, at least partly, participate in the non-genomic effect [14]. 
A variety of hormons like ACTH, β-, γ-lipotropin, α-, β-, γ-melanotropin (MSH), β-
endorpin, corticotrophin-like intermediary peptide (CLIP) and Met-enkephalin (Fig. 1.3) 
are all synthesized by post-translational cleavage of a large precursor molecule of about 
31kDa, called proopiomelanocortin (POMC), in the secretory granules of endocrine cells. 
The POMC gene encodes a polypeptide hormone precursor that undergoes extensive, 
tissue-specific, post-translational processing via cleavage by subtilisin-like enzymes known 
as prohormone convertases. Different cell types produce different concentrations of 
individual processing enzymes, so that depending on tissue type and the available 
convertases, processing may yield as many as ten biologically active peptides involved in 
diverse cellular functions. There are eight potential cleavage sites within the polypeptide 
precursor (Fig. 1.3). All these proteases cut next to pairs of positively charged amino acids 
(Lys-Arg, Lys-Lys, Arg-Lys, or Arg-Arg pairs) [65]. 
Proopiomelanocortin contains an N-terminal signal sequence which is suggested to be 
necessary for peptide expression [27] and is removed after synthesis.   
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In the anterior lobe of the pituitary the major secretory products are ACTH and β-
lipotropin cleaved on the Lys-Arg pairs of adjacent basic residues by the prohormone 
convertase 1 [3]. Whereas the cleavage of all the other peptide hormones occurs in cells 
other than corticotroph cells of the anterior pituitary. In the intermediate lobe the ACTH 
is then cleaved by prohormone convertase 2 at the Lys-Lys and Arg-Arg pairs to form α-
MSH and CLIP as the predominant products [8]. Beta lipotropin is degraded rapidly by the 
same proteolytic enzyme in the intermediate lobe and more slowly in the anterior lobe to 
γ-lipotropin and β-endorphin. Further cleavage these two peptides generates β-MSH and 
Met-enkephalin. 
Nevertheless, the POMC gene is also expressed in a variety of other tissues, such as the 
CNS, placenta, or the immune system, where tissue-specific differential post-translational 
processing may give rise to a different spectrum of peptides with a diversity of actions [16]. 
 
Fig. 1.3: Alternative processing pathways for the prohormone POMC (modified from [66]) 
Preliminary structural work on corticotropin isolated from acetone dehydrated human 
pituitaries indicated that it is similar to corticotropin from other species [17]. 
5’ – S124YSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF – 3’  mus musculus  
5’ – S138YSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF – 3’  homo sapiens 
Fig. 1.4: Amino acid sequence (one-letter-code) of ACTH in mouse and human 
ACTH is a highly conserved part of the prohormone POMC since only the amino acids at 
position 26 and 29 vary between mouse and humans (Fig. 1.4). Only its position in the 
POMC protein is different and the amino acid serine is found at position 124 in mouse 
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and at position 138 in humans. The biological activity of the ACTH molecule depends on 
the first 24 N-terminal amino acids  
The behaviour and the nature of ACTH is the very same in both individuals and illustrates 
that the AtT-20 cell line is a good model system for human ACTH studies.  
1.2.2 Biological activity 
The mechanism of ACTH action follows the classical rules of peptide hormones. ACTH 
travels through the blood stream to its target cells, the adrenal glands located on the 
kidneys, where it binds to its receptors on the adrenal cell membranes and results in 
cortisol secretion or physiological changes supporting fight-or-flight responses [61] in 
humans (Fig. 1.1).  
The primary role of adrenocorticotropin is to increase the synthesis and the release of 
cortisol by the adrenal cortex [35], to regulate the secretion of adrenal androgens [28], to 
increase adrenal blood flow [6], and to regulate its own release via a short-loop negative 
feedback mechanism [5], etc. 
1.3 CRH 
Corticotropin-releasing hormone (CRH or CRF), which is synthesized in the hypothalamus, 
plays a crucial role in the endocrine response to stress [10][29]. 
CRH is a 41-amino acid peptide hormone first isolated in 1981 by Vale et al. [37] that is 
derived from a 196-amino acid preprohormone by prohormone convertases 1 and 2. The 
chromosomal locus of the human corticotropin-releasing hormone (hCRH) gene is 
localized to band 8q13 on the long arm of chromosome 8 [2]. 
In response to stress CRH is secreted in minute quantities in vivo by the paraventricular 
nucleus of the hypothalamus into the portal vein, travels directly to the pituitary via the 
blood stream where it promotes ACTH secretion and synthesis. This action was simulated 
in vitro on the AtT-20 pituitary cell line in a simplified manner by adding low quantities of 
CRH as an extracellular stress stimulus and monitoring its real time ACTH response. 
CRH as well as cortisol activate genomic mechanisms via G-protein coupled receptors 
[14][48]. CRH binding to a CRH-receptor complex on the cell surface stimulates POMC 
expression in the nucleus via signalling cascades and the ACTH synthesis in the rough ER 
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and Golgi apparatus in the end. However, there is evidence of a non-genomic signalling 
pathway beside the genomic mechanism. CRH-binding to the same CRH-receptor complex 
or another receptor may induce the secretion of a reservoir of ACTH vesicles beneath the 
cell membrane via a fast-activating mechanism, but these mechanisms are still poorly 
understood. 
For the sake of completeness, beside its production in the hypothalamus, CRH is also 
synthesized in peripheral tissues, such as in T-lymphocytes or in the placenta. 
1.4  anti-ACTH IgG antibody 
1.4.1 Antibody structure 
Antibodies or Immunoglobulins are a family of structurally related glycoproteins 
synthesized in membrane-bound or secreted form by B-lymphocytes [60]. All antibodies 
have a common symmetric core structure of two identical disulfide-linked heavy chains 
and two identical light chains, each linked to one of the heavy chains (Fig. 1.5).  
 
Fig. 1.5: Structure and functional groups of an IgG antibody for labelling (from Thermo Scientific) 
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Each heavy chain of IgG is composed of a variable (VH) and three constant (CH) 
immunoglobulin domains of about 110 amino acids containing conserved sequences and 
intrachain disulfide bonds. Each light chain consists of one variable (VL) and one constant 
(CL) immunoglobulin domain. The N-terminal variable region of the heavy (VH) or light (VL) 
chain of IgG is responsible for the specificity of an antigen and thus for recognizing the 
ACTH molecule. As each antibody consists of two heavy chains with a single molecular 
weight of about 50 kDa and two light chains of about 25 kDa each the resulting total 
immunoglobulin molecular weight is approximately 150 kDa. 
 
Fig. 1.6: Production of monoclonal antibodies (from [60])  
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1.4.2 Monoclonal mouse anti-ACTH antibody 
For performing a precise FCS measurement it was important to label monoclonal 
antibodies which are identical antibody molecules specific for a particular region of the 
ACTH antigen. Labelled monoclonal antibodies are especially useful as capture antibodies 
in FCS-Immunoassays that require single-epitope specificity and an unchanging supply 
over many measurement cycles. 
The first and now generally used method for producing monoclonal antibodies of known 
specificity was described by Köhler and Milstein in 1975 (Fig. 1.6).  
These monoclonal antibodies are produced by B cell hybridomas which are cell lines 
derived by the fusion of a single normal murine B cell manufacturing anti-ACTH antibodies 
and an immortal B cell tumour line with no antibody production.  
A purified monoclonal mouse anti-ACTH antibody specific for the N-terminal region of the 
ACTH molecule (Fitzgerald Industries, Massachusetts, USA) was used binding specific to 
the amino acids 1-24 of the ACTH molecule. 
1.4.3 Functional groups for labelling 
A couple of functional groups are available on an IgG antibody for labelling (Fig. 1.5): 
♦ Primary amines (–NH2) are localized on lysine residues and the N-terminus and are 
distributed over the entire antibody. Since primary amines are abundant on an IgG 
antibody the labelling reaction occurs with the utmost probability. Therefore, this was 
the method of choice for labelling an antibody. 
 
♦ Sulfhydryl groups (–SH) on cysteine residues are generally involved in structural 
integrity of an antibody by forming disulfide bonds. Free sulfhydryls, which will react 
with the dyes, can be formed by selectively reducing disulfide bonds. However, only 
the reduction of one disulfide bond in the hinge region of the antibody won’t lead to a 
conformational change and thus to a change in specificity and functionality of the 
antibody. The probability that the dye reacts with these two free sulfhydryls is lower 
and the risk of creating a non-functional antibody is too high compared to that of 
primary amines. 
 
♦ Carbohydrate residues containing cis-diols are localized to the Fc region on antibodies 
and can be oxidized (–CHO) to create active aldehydes. Since carbohydrate residues 
are more abundant on polyclonal antibodies this option was dropped out. 
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1.5  Fluorescence 
In condensed systems, e.g. solutions, there are more pathways available to the excited 
molecule for dissipation of excitational energy. Some of these photophysical processes 
are intrinsic properties of the molecule and are unimolecular whereas others depend on 
external perturbations and may involve bimolecular collisions like quenching or electronic 
energy transfer [68]. Nevertheless a more careful consideration is ignored in this way 
because it would go too far, but, anyway, all these photophysical processes must occur in 
a time period less than the natural radiative lifetime of the molecule and priorities are 
established by their relative rate constants [68]. 
 
 Fig. 1.7: Simplified Jablonski diagram showing quantum yields and lifetimes (modified from [64]) 
The fundamental absorption and emission properties of dyes are often represented in an 
energy level diagram that shows the various electronic and vibrational energy levels that 
may exist in a molecule, together with the pathways that exist between these various 
distinct states (the ‘Jablonski’ diagram) [62]. A simplified Jablonski diagram that does not 
include effects due to solvent quenching, intermolecular quenching or FRET is shown in 
Fig. 1.7. The Jablonski diagram, named after the Polish physicist Aleksander Jablonski (his 
portrait is shown in Fig. 1.7 on the upper right side), elegantly depicts molecular 
  1 Introduction 
16 
electronic and vibrational energy levels illustrating the phenomenon of light absorption 
and emission [62].  
Tab.1.3 shows the unimolecular processes, which are represented in the simplified 
Jablonski diagram above as arrows, in more detail. At equilibrium, a fluorophore is likely 
to exist in the lowest vibrational energy level of the molecular ground state (S0). Upon 
absorption of a photon, whose energy closely matches an electronic transition in the 
fluorophore (under consideration of only a single-photon absorption), the fluorophore is 
excited to a high vibrational energy level in the first or second electronic singlet states (S1 
or S2), a process which occurs essentially instantaneously (10
-15 s). Rapid relaxation (~10-12 
s) then occurs to the lowest vibrational energy level of the first singlet state (S1) and is 
known as internal conversion.  
Photophysical process Transition Reaction 
Absorption  S0  Sn A + hν  A’* 
Internal conversion  Sn  S1 A’*  A* + heat 
Fluorescence emission S1  S0 A*  A + hνf 
Intersystem crossing S1  T1 A*  A3 + heat 
Phosphorescence emission T1  S0 A3  A + hνp 
Internal conversion S1  S0 A*  A + heat 
Reverse intersystem crossing T1  S0 A3  A + heat 
Tab.1.3: Various photophysical unimolecular processes occurring in a molecule (modified from [68]) 
A  molecules in ground state 
A*  molecules in first excited singlet state 
A’* 
molecules with excess vibrational energy in S1 state or excited to 
higher singlet states S2, S3, etc. 
A3 molecules in triplet state 
h Planck constant (= 6.626 x 10-34 J s) 
ν electromagnetic wave 
 
In a simplified view molecules in this equilibrated excited state can then lose energy 
through two primary mechanisms: 
♦ Fluorescence involving the immediate relaxation of the photon to the ground state 
(10-8 s), as well as delayed fluorescence: Energy may also be transferred back from 
the triplet state to S1 and result in delayed fluorescence with relaxation to S0 (not 
shown in Fig. 1.7). 
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♦ Phosphorescence (>10-6 s) is termed as a transition after a circuitous route from the 
first triple state (T1) to S0, which is much slower than a fluorescence relaxation 
transition from S1 to S0. Thereby energy of a molecule is first transferred from the first 
singlet state (S1) to the first triplet state (T1) by inter system crossing (ISC) or an ISC to 
a higher triplet level occurs followed by internal conversion to T1 (not shown in 
Fig. 1.7). 
 
Both mechanisms have in common that excitation energy is dissipated in form of light 
energy and thus can be monitored with even ultrasensitive detectors whereas in 
radiationless processes such as internal conversion and inter system crossing the excess 
of energy is lost to the environment as thermal energy and thus remains undetected.   
The fluorescent dye used for FCS should have a very low probability for a ‘spinflip’ from 
the S1 to the long-lasting triplet state, where no fluorescence occurs. 
Furthermore a fluorescent dye should have a high extinction coefficient at the laser 
wavelength of 488 nm, a bright fluorescence, an excellent photo and buffer stability and 
instrument compatibility.  
 
Fig. 1.8: Absoption and emission spectra of DyLight 488 fluorophor (from Pierce Biotechnology) 
Moreover it should display emission spectrally distinct from the excitation wavelength. 
For our approach we used a fluorophore (DyLight, Pierce Biotechnology) with an 
excitation wavelength of 488 nm (black absorption curve in Fig. 1.8) and an emission 
maximum of 518 nm (green emission curve in Fig. 1.8) which highlights with bright 
fluorescence, excellent photostability, buffer stability and instrument compatibility. The 
DyLight 488 dye is spectrally similar to other commercial available dyes from other 
companies, such as Alexa Flour 488, fluorescein or FITC.  
 
  1 Introduction 
18 
1.6  Fluorescence Correlation Spectroscopy 
1.6.1 Principle 
Fluorescence Correlation Spectroscopy (FCS) was introduced in the early 1970s by Madge, 
Elson and Webb [47]. This pioneering study was then followed by a number of successful 
FCS applications with impressive results in the last decades [46][45][50][52][54]. FCS has 
become a powerful tool especially in life sciences for studying supramolecular 
associations [42][48][49], DNA hybridization reactions [44][51], etc. 
FCS is a spectroscopic technique for studying molecular interactions in solution. It 
monitors the random motion of fluorescently labelled molecules inside a defined volume 
element irradiated by a focused laser beam.  
 
Fig. 1.9: Schematical drawing of an FCS setup (from [53]) 
The confocal FCS setup is illustrated schematically in Fig. 1.9. All measurements were 
performed on a laboratory-built FCS system consisting of a Confocor spectrofluorimeter 
(Carl Zeiss-Evotec, Jena, Germany) with the same equipment as previously published 
[48][49]. Intensity fluctuations were recorded by an avalanche photodiode (SPCM-CD 3017) 
and autocorrelated with a hardware correlator (ALV 5000, ALV, Langen, Germany) based 
on a two components fitting procedure. The obtained results showed that FCS can be 
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used for computationally eliminate diffusion times and particle numbers of two different 
fractions within a solution. 
The advantage of this technique lies in its simplicity and rapidity. However the time over 
which a single molecule-antibody complex can be observed is limited to its diffusion time 
across the observation volume which is typically less than one millisecond. 
In fact analyses of spontaneous, non-coordinated fluctuations due to Brownian motion 
can only be monitored, if the particle’s number is low enough so that each contributes 
substantially to the measured signal [53]. Thus FCS can even detect sample volumes of 
about 10-30 μl.  
1.6.2 FCS Immunoassay vs. ELISA 
An enzyme-linked immunosorbent assay (ELISA) is a very sensitive method for the 
quantitative detection of peptides, proteins, pharmaceuticals etc. in solution. A big 
palette of different ELISA techniques with anti-ACTH detection antibodies for measuring 
ACTH peptide concentrations is available on the market ranging from indirect to direct 





Fig. 1.10: The principle of a ‘sandwich’-ELISA (A) vs. that of FCS-Immunoassay (B) 
A fluorescent ELISA is a very sensitive technique for detecting even smallest amounts of 
molecules but it is a very expensive and time-consuming procedure and thus may have 
affects on the conformation and reactivity of molecules.  
The washing steps during each ELISA-procedure which should remove unbound material 
to diminish background signals are the “bottleneck” of this technique and, thus, are very 
  1 Introduction 
20 
time-consuming. The disadvantage of an ELISA is that it is expensive and laborious for 
measurements in high quantities. 
 FCS-Immunoassay fluorescent ELISA 
Sensitivity micro- to sub-nanomolar nano- to sub-nanomolar 
concentration range High Low 
Sample volume ~ 20 – 30 μl 100 μl 
Durability ~ 25 min  ~ 2 h 
Protein complex in solution on the surface 





(96 measurements per kit) 
Tab.1.4: FCS-Immunoassay compared with fluorescent ELISA 
Therefore, a novel method – the FCS-Immunoassay – was developed, which allowed fast 
and precise determination of the concentration of ACTH in the extracellular space of the 
cell culture. Values were measured nearly continuously in small aliquots of the 
supernatant. Only a single drop (20 μl) of the sample was necessary for measuring any 
protein concentration whereas about 100 μl sample had to be applied for an ELISA in a 
96-well plate. Furthermore additional incubation steps with e.g. blocking solutions or 
secondary antibodies were omitted because in contrast to ELISA no washing steps were 
necessary and molecules were directly detected by both antibodies in solution without 
any complicated construct on the layer of a well-plate. The main advantages of FCS-
Immunoassay are listed in Tab.1.4. 
1.6.3 FCS Immunoassay 
The first goal in establishing a new detection method was to get rid of the ‘mass problem’ 
of different particles diffusing through the focus meaning that the diffusion time of a 
molecule is proportional to the third root of its molecular weight and thus only significant 
changes in particle’s mass result in sufficiently different diffusion times, particle numbers 
and concentrations of the ACTH molecule. 
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3
rD Mτ ≈  
In principle two detection methods can be used for monitoring protein concentrations by 
means of FCS. Nevertheless for quantifying ACTH molecules in solution only the second 
method is sufficient as mentioned below.  
 
Method #1: ACTH detection with one anti-ACTH antibody 
There is no possibility to distinguish the ACTH-bound antibody fraction from the free 
unbound one as the molecular weight of the ACTH peptide hormone (4541 g/mol) is too 
low for significantly changes in particle’s mass. 
Method #2: ACTH detection with two anti-ACTH antibodies 
According to the ‘sandwich’-ELISA principle the ACTH molecule is captured by a labelled 
and an unlabelled monoclonal anti-ACTH IgG antibody each binding specific to a well 
defined region on the peptide hormone resulting in a complex with highly increased mass 
(~300kDa) and significantly changed diffusion properties compared to the free 
fluorescent one (~150kDa).  
For this method it is of indispensable importance that no crossreactivity of antibodies 
occurs. Otherwise we are confronted with the problem of method #1 and cannot 
distinguish between two crossreacted antibodies and two ACTH-bound antibodies! 
Tab.1.5 shows a variety of ACTH interactions theoretically occurring to both antibodies 
but only the formation of an antibody(unlabelled)–ACTH–antibody(labelled) complex was 
sufficient for this purpose. A high potential binding of both antibodies to the peptide 
hormone was achieved by the right setup (see chapter 4.4) and ensured an exact 
quantification of ACTH molecules along with a correction factor obtained by the labelling 
reaction (see chapter 4.1). Only in this way it was possible to computationally ‘scrape out’ 
the labelled unbound antibody fraction from the desired ACTH-bound form via 2-
component fitting. How experimental autocorrelation functions were evaluated by using 
a 2-component fit is discussed in detail in chapter 4.4.2. 
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~ 150 kDa ~ 230 μs 
 
~ 300 kDa ~ 1000 μs 
 
~ 154 kDa ~ 230 μs 
 
 
~ 154 kDa ~ 230 μs 
Tab.1.5: Possible ACTH/antibody formations in FCS-Immunoassay and its distinguishability 
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2 Aims 
The aim of our study was the in vitro quantification of a protein – appearing in one of the 
central systems in the human body – with one of the most upcoming detection 
techniques in the last years. 
Through important instrumental improvements in the last decades Fluorescence 
Correlation Spectroscopy (FCS) has become a powerful tool for kinetic measurements and 
binding studies. However, monitoring and quantifying the real time release of a protein in 
a cellular reaction network opens a fundamentally new application of FCS. 
2.1 Specific aim #1 
Optimizing Fluorescence Correlation Spectroscopy by establishing a novel solution-based 
technique as a counterpart to common used fluorescent ELISAs was the primary goal of 
study and obtaining highly resolved data in the period of interest for specific 
mathematical analysis in the future. 
2.2 Specific aim #2 
Employing this new assay to measure and quantify proteins of interest in an in vitro 
system represented the scientific application. For this purpose the HPA axis network, 
which plays a key role in the endocrine system of humans as well as in lots of diseases, 
was chosen as a model for our studies. The main focus of the work was the investigation 
of the real-time ACTH response of mouse AtT-20 pituitaries through different stress 
conditions.  
 
The obtained results will yield an optimal basis for mathematicians (Johann Radon 
Institute of Computational and Applied Mathematics, Austrian Academy of Sciences, Linz, 
Austria), which were involved in this project in collaboration with us, for quantifying the 
developed model and testing the impact of the considered mechanisms on the overall 
dynamics using methods from the field of inverse problems (Inverse Bifurcation Analysis, 
Inverse Eigenvalue Analysis and Parameter Identification) [55][56][57][58][59]. 
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3 Material  
3.1 Equipment 
3.1.1 Sample preparation 
 
Equipment Type Company/supplier 
Centrifuge  MIKRO 22R Andreas Hettich GmbH&Co.KG, Tuttlingen, Germany 
Gloves Handsafe® HPC Healthline Ltd., Morden, UK 
Incubator   HERAcell® Thermo Fisher Scientific Inc., Waltham, USA 
Laminar flow TWO 30 Faster Srl., Cornaredo, Italy 
Microplate 24-well IWAKI Glass Co., Funahashi, Japan 
Pasteur Pipettes  VWR International GmbH, Wien, Austria 
Pipette   PIPETMAN®P10  Gilson Inc., Middleton, USA  
Pipette PIPETMAN®P20 Gilson Inc., Middleton, USA 
Pipette PIPETMAN®P200 Gilson Inc., Middleton, USA 
Pipette PIPETMAN®P1000 Gilson Inc., Middleton, USA 
Pipette (one-way) 1ml Sterilin Ltd., Aberbargoed, UK 
Pipette (one-way) 5ml Sterilin Ltd., Aberbargoed, UK 
Pipette (one-way) 25ml Sterilin Ltd., Aberbargoed, UK 
Pipette controller accu-jet® pro Brand GmbH&Co.KG, Wertheim, Germany 
Pipette tips (micro) 0.5-10µl Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips 10-200µl Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips 200-1000µl Greiner Bio-One GmbH, Frickenhausen, Germany 
Rotor  1159 Andreas Hettich GmbH&Co.KG, Tuttlingen, Germany 
Suction pump LABOPORT® KNF Neuberger Inc., Trenton, USA 
Tube 50ml conical tube Sterilin Ltd., Aberbargoed, UK 
Tube 1.5ml Eppendorf VWR International GmbH, Wien, Austria 
 
3.1.2 Cell counting  
 
Counting chamber Bürker-Türk LO-Laboroptik GmbH, Friedrichsdorf, Germany 
Inverted Microscope Axiovert S100TV Carl Zeiss Jena GmbH, Jena, Germany 
Pipette PIPETMAN®P20  Gilson Inc., Middleton, USA 
Pipette tips 10-200µl Greiner Bio-One GmbH, Frickenhausen, Germany 
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3.1.3 Labelling 
 
Antibody Labelling kit DylightTM488 Pierce Biotechnology, Rockford, USA 
Centrifuge MIKRO 22R Andreas Hettich GmbH&Co.KG, Tuttlingen, Germany 
Pipette PIPETMAN®P200 Gilson Inc., Middleton, USA 
Pipette tips 10-200µl Greiner Bio-One GmbH, Frickenhausen, Germany 




Ar-laser  LASOS Lasertechnik GmbH, Jena, Germany 
Spectrofluorimeter ConfoCor® 2 Carl Zeiss Jena GmbH, Jena, Germany 
Objective  Carl Zeiss Jena GmbH, Jena, Germany 
Chambered coverglass LabTekTM Nalge Nunc International KK, Tokyo, Japan 
Avalanche photodiodes  Perkin Elmer Inc., Massachusetts, USA 
Hardware autocorrelator  ALV GmbH, Langen, Germany 
PCR tubes  Brand GmbH&Co.KG, Wertheim, Germany 
Pipette PIPETMAN®P10  Gilson Inc., Middleton, USA 
Pipette PIPETMAN®P20 Gilson Inc., Middleton, USA 
Pipette PIPETMAN®P100 Gilson Inc., Middleton, USA 
Pipette tips (micro) 0.5-10µl Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips 10-200µl Greiner Bio-One GmbH, Frickenhausen, Germany 
Pipette tips 200-1000µl Greiner Bio-One GmbH, Frickenhausen, Germany 
 
3.2 Chemicals and solutions 
 
ddH2O  Millipore, Massachusetts, USA 
Ethanol   Sigma-Aldrich Inc., St. Louis, USA 
Rhodamine 6G   Sigma-Aldrich Inc., St. Louis, USA 
Sodium bicarbonate  Sigma-Aldrich Inc., St. Louis, USA 
Trypsin (1x), 0.25% in PBS PAA Laboratories GmbH, Pasching, Austria 
DMEM  Sigma-Aldrich Inc., St. Louis, USA 
PBS (100x) Sigma-Aldrich Inc., St. Louis, USA 
Penicillin/Strepomycin (100x) EuroClone S.p.A., Siziano, Italy 
 
 




AtT-20 cell line  ATCC, Rockville, USA 
anti-ACTH IgG antibody  monoclonal (C-term.) Fitzgerald Industries International, Concord, USA 
anti-ACTH IgG antibody  monoclonal (N-term.) Phoenix Pharmaceuticals Inc., Belmont, USA 
CRH  Sigma-Aldrich Inc., St. Louis, USA 








Carl Zeiss Jena GmbH, Jena, Germany 
 
FCS fitting program I FCS ACCESS Fit Carl Zeiss Jena GmbH, Jena, Germany 
FCS fitting program II  Prof. Köhler’s group (running on LINUX) 
Microsoft® Word  Office 2007 Microsoft Corporations, Redmond, USA 
Microsoft® Excel Office 2007 Microsoft Corporations, Redmond, USA 
OriginPro® Version 8 OriginLab Corporation, Northampton, USA 
Symyx Draw Version 3.2 Symyx Technologies Inc., Sunnyvale, USA 
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4 Methods 
4.1 Fluorescent labelling of antibodies  
For further measurements the quality of antibodies is of immense importance. To avoid 
long labelling reactions and maybe the degradation of antibodies as a consequence of 
temperature shift, the selection of the reactants plays a decisive role. As mentioned 
below the durability of a nucleophilic substitution is dependent on the binding speed in 
all steps and, thus, on the reactivity of both reactants: the nuceophile and the leaving 
group. 
The conjugation of a monoclonal mouse anti-ACTH (N-terminal) IgG antibody to a DyLight 
488 dye was performed by a DyLight Microscale Antibody Labelling Kit (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA in cooperation with Pierce Biotechnology, 
Rockford, USA). This kit contained all sufficient reagents to obtain fluorescently labelled 
proteins in a few simple reaction steps. It was designed for labelling and subsequently 
purifying 100µg (1mg/ml) of anti-ACTH IgG antibodies. 
The NHS ester, the most commonly used reactive group for labelling proteins, reacts 
ideally with all five primary amines – located on the lysine side chains of the antibody – 
forming a stable, covalent amide bond by releasing the NHS group. To avoid nonreactivity 
of fluorescent dyes it is very important to store NHS esters at -20°C till the labelling 
reaction occurs. 
 
Fig. 4.1: Nucleophilic substitution on the carboxyl group (modified from [63])  
A small trip to organic chemistry clarifies and demonstrates the mechanism of the 
labelling reaction in detail. The nucleophilic substitution on the carboxyl group occurs via 






L = OSu     R = fluorophor 
Nu = R1NH2    R1 = antibody 
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reaction occurs is influenced by two facts: On the one hand the NHS-ester is a good 
leaving group because it favours a nucleophilic attack by delocalizing the negative charge 
from the carbon atom very well and thus leading to a partially positive charged carboxyl 
carbon atom. On the other hand primary amines are stronger nucleophiles than 
secondary or tertiary amines as their electron cloud is easier deformable, easier 
polarisable since the negative charge is clustered to the free electron pair at the nitrogen 
atom and not partially distributed over the residues, which are both hydrogen atoms. 
 
Addition step 
The reaction starts with a nucleophilic attack on the carboxyl carbon atom of the trigonal, 
sp2-hybridized NHS-ester forming a tetrahedral intermediate, where the carbon atom is 
sp3-hybridized and bound to four residues.  
 
Elimination step 
The negative charge in the intermediate state is now delocalized at the oxygen atom and 
results in a very instable C–L bond. Immediately afterwards the nucleofug – the leaving 
group – with the binding electron pair is eliminated, and the oxygen atom provides its 
free duplet to form a stable, trigonal, sp2-hybridized carboxyl carbon atom again. 
 
Fig. 4.2: Labelling reaction of Fluorescein NHS ester to a primary amine of an IgG antibody  
5-Carboxyfluorescein N-succinimidyl ester      Fluorescein Carboxylamid 
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Recapitulatory the reactive nucleofug N-succinimide is substituted by an amine, which is a 
strong nucleophile in turn. The end product of this nucleophilic substitution is a labelled 
antibody. Fig. 4.2 shows the simplified form of the labelling reaction considering the 
chemical structure of all reactants if all proton transfer steps are excluded. The different 
colours of atoms and bonds should demonstrate the dynamic of electrons transfers in this 
substitution reaction. 
4.1.1 Protein Labelling  
100 µl of the prepared antibody solution (1 mg/ml) was added to the vial of the NHS 
ester, inverted 10 times and then centrifuged (Hettich-Centrifuge MIKRO 22R, Hettich-
Rotor 1159) to enable an optimal labelling reaction in a short time. The collected reaction 
mixture was incubated for 60 minutes at room temperature protected from light. 
4.1.2 Protein Purification 
Subsequently, the protein purification was performed by column chromatography. The 
column was calibrated with 100 µl of a premixed uniform silica gel suspension which was 
filled into a spin column that contained a filter prior to the exit port to avoid effluence of 
the silica particles (Sephadex G-25M). Centrifugation for 45 seconds at 1000xg (3200 rpm) 
and 4°C removed the PBS solution and bedded the silica particles. The collected reaction 
mixture from the labelling step – a suspension of labelled antibodies and free unbound 
dyes – was loaded on the spin column. 
Due to the fact that molecules migrate through the stationary phase with different 
retention times, labelled antibodies were separated from non-reacted dyes by modified 
silica particles of the stationary phase, which acted like a molecular filter: Non-conjugated 
fluorophores remained in the pores of the silica particles and, thereby, could be removed 
by gel filtration, because they retended in the stationary phase (visible as a coloured 
phase) whereas labelled and unlabelled antibodies were not retended and passed 
through the column because of a too small pore size of the stationary phase. The 
migration of the reaction mixture through the stationary phase was accelerated by 
centrifugation for 45 seconds at 1000xg (3200 rpm) and 4°C. The purified conjugates were 
collected in an Eppendorf tube and stored in single-use aliquots at -20°C to avoid 
repeated freeze/thaw cycles. 
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4.1.3 Protein ratio estimation 
For all further measurements it was of indispensable importance to verify the existence of 
these purified labelled antibodies on the one hand and to determine the degree and the 
exact concentration of them on the other hand by the use of photometry. 
Lambert Beer's law is a fundamental equation in optical spectroscopy and expresses that 
the amount of light emerging from a sample is diminished by three physical phenomena:  
• the amount of light absorbed in any volume (concentration),  
• the distance the light travels through the sample (optical path length) and  
• the wavelength-dependent probability that a photon will be absorbed by the 
sample (extinction coefficient).  
 











 A measured absorbance   
 I intensity of the absorbed light   
 I0 intensity of the initial light beam c concentration of absorbed sample [M] 
 ε extinction coefficient [M-1cm-1] 
 
d optical path length [cm] 
 
Based on the fact that upon protein conjugation the absorption maximum (Amax) of the 
bound fluorophore shifts to the right of the spectra an absorption spectra (see Fig. 4.3 
and Tab. A.1) was recorded with a spectral photometer and the protein concentrations of 
labelled and unlabelled antibodies were calculated afterwards according to Lambert-Beer 
law. For this purpose 5 μl of the collected purified conjugates were added to 147.5 μl PBS 
(dilution of 1:30.5) in a quartz cuvette of 1 ml volume. PBS was used as the blank in this 
measurement.  
As mentioned above the absorption maximum (Amax) of the dye shifts to the right of the 
spectrum from 488 nm to 493 nm upon protein conjugation and was considered as a 
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The UV absorption maximum at 280 nm wavelength, which was caused by the two 
aromatic amino acids Tryptophan and Tyrosine of the antibodies, indicated the presence 
of antibodies in the sample. 
 
Fig. 4.3: Absorption spectra of DyLight488 
 
In 1975 the Norwegian physician Per Brandtzaeg recommended the following formula to 
calculate protein concentrations in solution 




















labelled ab,  
A280 = 0.0526     CF = 0.147 
Amax = A492 = 0.0107    DF = 30.5 
εIgG ~ 210000 M
-1cm-1   d = 1 cm  
εflour ~ 70000 M
-1cm-1 
 
































Degree of labelling 
 
About 63% of the anti-ACTH IgG antibodies were successfully labelled with the 
fluorophore whereas the rest remained unlabeled in solution. Additional purification 
steps might enhance the degree of labelled antibodies in a solution but would result in 
the lost of a great amount of labelled antibodies as well. Nevertheless only fluorescent 
antibodies can monitor random motions of an antibody-ACTH complex inside a defined 
volume element during FCS measurements.  
Assuming that the binding event of a labelled antibody to the N-terminal region of the 
ACTH molecule occurred in the same degree as its successful labelling reaction, a 





Correction factor (CF) for ACTH concentration: 
 
 
4.2 Cell culture  
Cell seeding and incubation of AtT-20 cells were performed as described for the static 
ACTH release experiments [40] and was partially modified for this experimental approach. 
4.2.1 Cell line and cell culture medium 
AtT-20 cells (ATCC No. CCL-89) were purchased from the American Type Culture 
Collection (ATCC, Manassas, USA) and passaged at a subcultivation ratio of 1:4 every 5 
days. For these experiments only cells with a passage number up to five were used. 
The base medium used for this cell line was Dulbecco’s Modified Eagle’s Medium 
(DMEM). For a complete growth medium cell culture reagents were used in conjunction 
with the base cell culture medium to provide essential nutrients like FBS for the AtT-20 
cell growth and to support cell maintenance: this was achieved with the antibiotics 
penicillin and streptomycin on the bacteriological side and with sodium bicarbonate on 
the chemical side. The bottom line was to avoid apoptosis of the AtT-20 cells induced by 
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pathogens and to remove any acidic impurities from the media by decomposing to water 
and the volatile carbon dioxide.  
  NaHCO3 + H
+  →   Na+ + H2CO3 
  H2CO3   →   H2O + CO2↑ 
  NaHCO3 + H
+  →   Na+ + H2O + CO2↑ 
Therefore the base medium was supplemented with a final concentration of 10% foetal 
bovine serum, 1.5 g/l sodium bicarbonate, 10 u penicillin and 10 μg streptomycin. 
4.2.2 Seeding AtT-20 cells  
For this static ACTH release experiment the cells were seeded onto polystyrene 24-well 
tissue culture plates (Nalge Nunc International, Japan) at a density of 1.0x104 cells/ml in 
each 16 mm well and grown in 1ml DMEM complete medium for 2-6 days without any 
medium change. AtT-20 cells were maintained in an incubator (HERAcell®, Thermo 
Scientific, USA) at 37°C, 6% CO2 and 95% relative humidity. Samples were seeded in 
duplicate to ensure reproducible results.  
4.2.3 Stimulating AtT-20 cells 
CRH is one of several stress factors which stimulates the ACTH response in pituitary gland 
cells (see CRH). 
A dose of 10 nM was chosen because it was shown in FCS measurements to induce 
maximal ACTH response in AtT-20 cells between 5-20 nM CRH (data shown in Results and 
Discussion). For this purpose the cells were treated with 10 nM CRH in the stationary 
phase after incubation times of 92 hours and 114 hours. 
4.2.4 Preparing samples for FCS measurement and cell counting 
For measuring the cell population and the ACTH concentration, the cells had to be 
separated from the extracellular space. Whenever working with cell culture all 
experimental steps were carried out under sterile conditions in a laminar flow. Finally 
quantitative answers for the secreted ACTH concentration per cell as well as for the ACTH 
rate per cell were given (Fig. 4.4). 
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Fig. 4.4: Reduced overview of preparing AtT-20 cells (l.) and the supernatant (r.) for measurements 
Supernatant (ACTH) 
The supernatant, which mainly composed of the complete culture medium, secreted 
hormones, detached – mostly apoptotic – cells, degradation products and other trash, 
was removed careful from the cell layer and transferred into an Eppendorf tube. 
Subsequently the centrifugation at 3200 rpm and 37°C for 10 minutes ensured the 
separation of cell and trash material (pellet) from low-molecular weight compounds, 
which still remained in the supernatant.  
As the FCS is a very sensitive spectroscopic technique, this step was of indispensible 
importance to avoid autofluorescence of the cell surface or unspecific antibody 
interactions with membrane proteins that may influence the results. Thereby the 
supernatant (about 1 ml) was transferred into a sterile tube and incubated at 37°C till FCS 
measurement occurred.  
However the resulting cell pellet with an actually small amount of intact cells had to be 
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Cell pellet (AtT-20) 
Once the medium was removed 200 μl of 0.25% (w/v) trypsin solution was added and the 
cells incubated at 37°C and 5% CO2 for 5 minutes to achieve proteolysis of the adhesion 
matrix. Afterwards the cell layer was briefly rinsed with 800 μl DMEM to stop 
trypsinisation and transferred into that tube including the cell pellet of the pre-performed 
supernatant isolation. The cell layer cell suspension was gently mixed and loaded on a 
Bürker-Türk counting chamber immediately afterwards to calculate the number of AtT-20 
cells. 
4.3 Cell counting 
The Bürker-Türk chamber, which was used in all measurements for calculating the 
population of AtT-20 cells, is one of various counting chambers available on the market 
differing only in their design of the counting net and the chamber depth. 
  
Fig. 4.5: Counting net and countable areas (in blue) of a Bürker-Türk counting chamber 
The countable area (in Fig. 4.5 in blue) of a Bürker-Türk chamber consists of a large 
square in the middle which is divided into four times four group squares of 0.04 mm2 
each. Taking the chamber depth of 0.1 mm into account, the concentration of AtT-20 cells 
in a solution can be calculated as the number of cells in each group square corresponds to 
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a fixed volume of 0.004 mm3. Through the low cell numbers in each group square, the 
countable area was expanded to all 16 group squares to diminish the probability of 
counting errors. 
Immediately after completing each count the cover glass and the counting chamber were 














Counted area 16 group squares = 16 x 0.04 mm2 = 0.64 mm2 
Chamber depth 0.1 mm 
 
Regarding to these parameters the following simplified formula formed the basis for all 









Simplified calculation formula 
 
 
4.4 FCS-Setup  
4.4.1 FCS-Measurement 
However, from the instrumental as well as the chemical point of view a suitable 
measurement requires the right setup, which had to be found in a few tens of FCS 
measurements by changing the ratio of the antibodies, sample and buffer solution among 
each other. A variety of mechanisms can influence FCS measurements: dynamic 
photobleaching of molecules to a dark state, photo-induced isomerisation, protonation of 
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chromophores, photon anti-bunching and other processes are of particular concern and 
cause unwanted background signals. 
Even lowest signal/noise-background during FCS measurements that allows detection of 
all low-abundance ACTH molecules with great selectivity and sensitivity was the goal of 
this setup. Finally the right adjustment enabled quick, constant and reproducible 
measurements as the shape sigmoid run of the autocorrelation function and the constant 
fluorescence intensity of each photon illustrated in chapter 4.4.2. 
For this reason labelled as well as unlabelled antibodies were added in excess to the 
sample compared to the number of ACTH molecules expected in solution to ensure a 
quick and high potential binding of both antibodies to all ACTH molecules and to calculate 
exact ACTH concentrations by means of FCS in the end.  
In fact FCS cannot be performed in too concentrated solutions with many fluorophores in 
the observed volume. Less fluorophores result in more fluctuations and more 
fluorophores result in smaller fluctuations and a more constant average signal [64]. 
 
‘Detection mixture’ for FCS measurements 
Therefore, PBS (1x), purified antibody conjugates (100 μg/ml) binding to the N-terminal 
region of the ACTH molecule, unlabelled IgG antibodies (100 μg/ml) specific for  the C-
terminal region of adrenocorticotropin and a sample aliquot including ACTH molecules of 
unknown concentration were united in a volume ratio of 8 : 1 : 1 : 10, slightly stirred and 
incubated for 20 min at 37°C.  
In a meanwhile a drop of the organic fluorescent dye Rhodamine 6G (diluted 1:200) was 
used to automatically position the chambered coverglass (Nalge Nunc International, 
Japan) in focus of the confocal optics of the spectrofluorimeter by a scanning procedure 
as well as to automatically adjust the pinhole to its right position (for the pinhole                 
x = 4.739 mm, y = 4.812 mm and z = 6.294 mm; for the focus 5.600mm). A pinhole, which 
is introduced in the image plane of confocal optics, is responsible for limiting the 
detection volume in axial direction and thus blocking all light not arising from the focal 
region. The pinhole size was set to 45 μm, resulting in a confocal volume element of    
0.17 μm in the lateral and 2.4 μm in the axial dimension.  
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For focussing light in a total space element of about 0.5 femtolitres small sample volumes 
(15-30 μl) are sufficient for FCS measurements. 
After 20 min incubation time, a drop of sample was pipetted on the chambered 
coverglass and the fluctuations in fluorescence intensity were monitored in series of 30 
measurements with identical setup (measurement time: 10 s; correlator scaling: 10 s) for 
each sample.  A correct positioning was re-evaluated after 20 measurement series.  
4.4.2 Calculating autocorrelation function G(τ) 
The number of fluorescent molecules entering and leaving the detection volume (10-15 l) 
fluctuates incessantly. Binding events result in slower fluctuation components and 
modulate the fluorescence signal, which is additionally influenced by triplet crossing 
causing blinking on a characteristic microsecond-timescale. Fig. 4.6 shows that the 
fluorescent dye ideally displayed emission which persisted for a long time. This 
photostability of the fluorescent signal made it possible to monitor fluctuations via a long 
timescale. 
 
Fig. 4.6: Fluorescence Fluctuations monitored in a FCS measurement 
As a higher number of measurements for each sample diminishes its deviation of the 
mean value and, thus, increase the accuracy of results enormously, a spate of 30 to 40 
fluctuation measurements was carried out for each sample with identical FCS setup.  
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Subsequently, fluctuations were analyzed statistically by the autocorrelation function to 
yield accurate results. In addition, a model which incorporates descriptions of the sources 
of fluctuations was used for fitting this function to determine the physical parameters of 
interest.  
The amplitude and speed of the fluctuations were used to calculate the correlation 
function. The intersection point of the autocorrelation curve with the ordinate is inversely 
proportional to the average number of fluorescent particles being observed. The red 
points on the curve in Fig. 4.6 indicate the different diffusion times derived from the 
function. A diffusion time of about 230 μs is related to the free antibody fraction whereas 
antibody(labelled)–ACTH–antibody(unlabelled) complexes need longer diffusion times 
through the focus of about 900-1200 μs. 
 
Fig. 4.7: Schematic representation of an autocorrelation function for a sample with 2 diffusion properties 
The normalized autocorrelation function G(τ) describes fluctuations of a signal F(t) from 
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where the angular brackets in the function represent the ensemble average and τ is 
known as the delay or correlation time over which the fluctuations are compared. 
G(τ) depends on the measurement geometry and on the diffusion properties of the 
fluorescent species. The Stokes-Einstein relation mathematically describes the 
translational diffusion coefficient of a particle in a viscous medium [62], 
f
Tk
D =  
D Diffusion coefficient 
k Boltzmann constant 
T Temperature 
f Friction coefficient for the particle in the fluid 
 
where f depends on the geometry (Stokes radius) as well as the surrounding solution 
(viscosity of the solvent), and is given by [62] 
rηπ6f =  
f friction coefficient for the particle in the fluid 
η viscosity of the solvent 
r hydrodynamic radius (Stokes radius) 
 
For a single diffusing species (a one component model) in a Gaussian confocal volume the 



























where N is the particle number and τD the molecular diffusion time of the fluorescent 
molecule moving through the confocal volume in an axial (z) to radial (r) dimension [48][49]. 
The molecular diffusion time for a one photon excitation is given by the following 
relationship to the diffusion coefficient D [cm2 s-1] 
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D =  
The obtained autocorrelation functions were evaluated using a two component model by 
fixing the diffusion time of component 1 which was achieved from one component fitting 
of labelled antibodies (see the equation for a one component model above).  
The analytical formula for the two component model, which was successfully applied in 
previous works of our scientific group [48][49], was used in a modified form (including triplet 
state in component 1) for this approach and is given by 
















































This yields values of diffusion times (τD1, τD2) and of the related mole fractions Y and (1–Y) 
for the two components. Based on this autocorrelation function the 2-component curve 
fit permits the direct reading of four parameters in the detection volume (Fig. 4.7):  
♦ the diffusion time (τD1) of component 1 
♦ the number of particles (p1)of component 1 
♦ the diffusion time (τD2) of component 2 
♦ the number of particles (p2)of component 2 
 
Only in this way it was possible to computationally eliminate the desired ACTH-bound 
form (component 2) from unbound fluorescent antibodies (component 1) in the sample.  
Assuming that exactly as many antibody(labelled)–ACTH–antibody(unlabelled) complexes 
were formed as ACTH molecules remained in solution, the concentration of ACTH was 
directly calculated from the number of particles of component 2.  
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5 Results and Discussion 
5.1 Cell growth studies on AtT-20 pituitaries 
As the main focus of our study was the investigation of stress response of pituitary glands 
within the HPA axis, experiments were centred on the AtT-20 cell type.  
Prior to all in vitro studies a stable population of AtT-20 cells had to be established in a 
complete medium without any cell stimuli (e.g. CRH or cortisol) and the stress-
independent basal ACTH level had to be measured in a second step.  
Recent data supported well-known investigations from the past [40] and indicated that 
beside unwanted environmental factors (listed in Tab.1.2) the behaviour of the growing 
curve is strongly influenced by the initial cell concentrations. The higher the cell 
population from the outset, the sharper and quicker the increase in the growing curves 
during exponential phase (Tab.5.1). 
Live image studies – performed with Zeiss AxioCam MRm by focussing on the cell layers in 
each 16mm-well – showed different characteristics in morphology and the same 
tendency in cell growing as mentioned above. Tab.5.2 corroborates this hypothesis of cell 
behaviour and illustrates that the cell population increases from the left to the right side 
(in each row of Tab.5.2) due to higher seeded cell numbers.  
Initial cell concentrations of 5x104 – 1x105 cells per ml indicate a far quicker growing 
process (pointed out in columns in Tab.5.2). However, a population of 5x105 AtT-20 cells 
per ml is too high and the growing process too quick for investigating anything. Already 
after about 30 hours cells run through the stationary phase, because no distinctive 
increase of the cell population is observed in the next 22 hours. A population decrease of 
7% cells (Tab.5.1) indicates that the balance of living to dead cells is shifted to negative 
cell growth and the majority of cells begin to shrink after already 44 hours and go into 
apoptosis after 70 hours, which is observable as a cell detachment from the layer (see 
right column in Tab.5.2).  
 







cell counts  
per 16 squares 
total 
 polulation 
+/-  total 





[cells/ml] [h]         [cells/ml] [cells/ml] [cells/ml] [%] 
5.0×103 22 1 0 1 0 0 1 1 1 9765.63 7324.22 4766 195.31 
1.0×104 22 2 1 1 0 1 2 1 1 17578.13 6835.94 7578 175.78 
5.0×104 22 7 3 4 4 5 3 7 6 76171.88 21484.38 26172 152.34 
1.0×105 22 9 11 10 9 9 12 10 12 160156.25 16601.56 60156 160.16 
5.0×105 22 10 12 12 9 11 9 10 10 648437.50 15136.72 148438 129.69 
              
5.0×103 44 1 2 1 1 1 0 1 1 15625.00 3906.25 5859 160.00 
1.0×104 44 3 2 2 1 2 2 2 1 29296.88 6835.94 11719 166.67 
5.0×104 44 9 11 12 14 10 12 14 10 179687.50 23437.50 103516 235.90 
1.0×105 44 20 25 26 21 19 19 24 21 341796.88 36621.09 181641 213.41 
5.0×105 44 15 13 17 12 10 16 14 13 859375.00 27343.75 210938 132.53 
              
5.0×103 76 2 3 1 2 2 3 1 2 31250.00 7812.50 15625 200.00 
1.0×104 76 8 6 9 9 10 8 9 7 128906.25 15625.00 99609 440.00 
5.0×104 76 19 16 16 20 15 17 21 19 279296.88 29296.88 99609 155.43 
1.0×105 76 6 8 7 7 9 6 8 6 445312.50 14160.16 103516 130.29 
5.0×105 76 14 16 11 13 13 10 14 12 804687.50 21972.66 -54688 93.64 
 
 
   
 
Tab.5.1: Cell growth studies on AtT-20 pituitaries by cell counting 
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Recapitulatory, the behaviour of AtT-20 cell growth is dependent to various populations 
of AtT-20 cells at the beginning. Furthermore an initial cell number higher than 104 cells 
per ml would result in temporally shorter phases of each AtT-20 cell growing circle and, 
thus, in temporally too short time windows for measuring real-time ACTH response to 
stress factors. 
5.2 AtT-20 counts (seeded initial cell concentration: 104 cells/ml) 
With respect to the quantification of our model the data further suggested, that in case of 
no medium change the stationary phase was most suitable for stimulating AtT-20 cells. An 
optimal use of this relatively short phase was achieved by adapting the initial cell 
concentration of 104 cells per ml for all in vitro experiments.  
 
Fig. 5.1: AtT-20 cell growing curve compared with its total basal ACTH level over 138 h incubation time  
The resulting time window for performing model studies (red area in Fig. 5.1) was 
increased to about 24 hours – starting after 92 hours and ending after 114 hours total 
incubation time – compared to only 14 hours for an outset of 5x104 cells per ml in the 
stationary phase, and thus permitted the measurement of ACTH levels over a long period 
































92h       114h 
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of time. Furthermore the constant low ACTH output rate per cell and the constant 
number of cells in the stationary phase allowed the detection of even slight changes in 
ACTH levels. 
5.3 ‘Idle currents’ in the stand-by mode of AtT-20 cells 
The basal ACTH rate, which indicates a permanent and constant secretion of this peptide 
hormone in AtT-20 cells, is triggered by inevitable signals (Tab.1.2) in the extracellular 
space caused by handling [31] and, thus, of immense importance for interpreting the ACTH 
response to stress in the right way. Metaphorically spoken a basal level to a certain time 
is the ‘idle current' of ACTH secreted by the AtT-20 cell.  
Therefore fluctuations of the basal ACTH level are observable depending on whether an 
up- (e.g. CRH) or down-regulating factor (e.g. cortisol) binds to the receptors on the cell 
surface.  
time population +/-   ACTH +/- ACTH/cell ACTH/cell/h 
[h] [cells/ml] [cells/ml] [nM] [nM] [nM.ml/cell] [nM.ml.h/cell] 
0 10000 0 0 0 0 0 
20 16602 9156 6.249 0.372 9.4651E-04 4.7325E-05 
40 24415 9766 11.253 0.691 6.4049E-04 3.2025E-05 
65 67709 19098 13.684 0.967 5.6140E-05 2.2456E-06 
92 154390 32039 14.391 0.660 8.1608E-06 3.0225E-07 
114 205163 35327 15.027 0.666 1.2523E-05 5.6925E-07 
138 171875 24306 15.685 0.529 -1.9770E-05 -8.2375E-07 
Tab.5.3: Basal ACTH concentration and basal output rate in ‘stand by’-mode 
The basal ACTH secretion is characterised by a strong increase in the first 65 hours of 
incubation (Tab.5.3, illustrated in Fig. 5.2). Nevertheless a plateau level of ACTH is 
reached after an 80-hour incubation period. It could be interpreted as a shut down 
mechanism of the secretion machinery in AtT-20 cells due to a large pH change to an 
acidic milieu in the medium mainly caused by the degradation products of AtT-20 cells 
and nutrition depletion in the medium.  
Fig. 5.3 points out the basal ACTH rate per cell in one hour, which represents the most 
significant value as the cell population is taken into account as well. Thereby the same 
tendency as discussed for the total basal ACTH concentrations in the extracellular space 
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can be observed: A high ACTH secretion level per cell in the first 60 hours, followed by a 
reduced ACTH output to a minimum in the stationary phase (between 95 hours and 120 
hours incubation time) as a result of nutrient lost and the shutdown of cell growth.  
 
Fig. 5.2: Total basal ACTH level of AtT-20 cells over 138 h incubation time 
As soon as the nutrient’s level diminishes radically (after about 120 hours incubation 
time), the cell has to constrain its metabolism to a minimum to survive. Since the 
pathway of ACTH synthesis only plays a subsidiary role for AtT-20 cells in case of life or 
death the secretion of ACTH is shut down first to ensure cell survival.  
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5.4 Molarity of a signal controls its ACTH response 
The first goal of our study was to find the right extracellular CRH concentration for 
measuring highly different ACTH secretion levels compared to those in the basal state. 
As the firing frequency of action potentials in neurons reflects the magnitude of intensity 
of any stimulus the same is true in case of hormone signalling in the HPA axis network. 
Due to higher stress intensities, neurons located in the periventricular hypothalamus 
increase the frequency of CRH release into the blood of the portal circulation. Within 15 
seconds CRH travels in short distance to the anterior pituitary where it stimulates ACTH 
release [61]. Our data (Tab.5.4 and Tab.5.5) of an in vitro HPA axis model suggests that the 
molarity of CRH controls its ACTH response in AtT-20 pituitaries and affects its cell 
growing as well. An incubation of CRH in a concentration range of 5-10 nM over 22 hours 
showed a strong increase in the total ACTH level (Fig. 5.5B), as well as in the cell 
population (Fig. 5.6A), which indicates that CRH in low molarities mediates a higher rate 
of ACTH secretion (Fig. 5.4), whereas CRH concentrations higher than 54 nM won’t have 
any significant effects on ACTH secretion rate compared to basal levels.  
Several anterior pituitary hormones exert short-loop negative feedback on the 
hypothalamus resulting in lower or even inhibition of CRH output rate [69] in vivo. 
Surprisingly this short-loop negative feedback mechanism has no influence for our in vitro 
model as no hypothalamic cells exist, which would generate a response.   
However, an adaptive function of this feedback mechanism is that it maintains the plasma 
concentration of the final hormone in a sequence relatively constant whenever a disease-
induced primary change occurs in the secretion or metabolism of that hormone [69]. 
Transformed to our study there could be evidence of a protective mechanism in AtT-20 
cells, which is triggered by a CRH overload in the extracellular space, beside the described 
short-loop negative feedback, which down-regulates ACTH secretion as well as cell 
growth if a threshold of stress intensity is reached leading to a far increased ACTH output 
rate and affecting the balance of homeostasis. 
These results suggested that the highest ACTH response exerts from extracellular CRH 
concentrations of 5-20 nM. Therefore a stress signal of 10 nM CRH was used for all 
further measurements on AtT-20 pituitaries. 





+/-   
population 




[h]  [cells/ml] [cells/ml] [cells/ml] [nM] [nM] 
92  154390 32039  14.391 0.660 
114  205163 35327 50773 15.027 0.666 
114 +5nMCRH(22h) 335938 27344 181548 16.771 0.916 
114 +10nMCRH(22h) 324219 19532 169829 16.898 1.065 
114 +36nMCRH(22h) 302084 28936 147694 16.151 0.904 
114 +54nMCRH(22h) 237500 22500 83110 15.364 1.389 
Tab.5.4: Cell- and ACTH response through different CRH concentrations (part I) 
time 
 ACTH 
after 22h CRH ACTH/cell ACTH rate 
+/- basal  
ACTH rate 
[h]  [nM] [nM.ml/cell] [nM.ml.h/cell] [nM.ml.h/cell] 
92  0    
114  0.636 1.2523E-05 5.6925E-07  
114 +5nMCRH(22h) 2.380 1.3108E-05 5.9580E-07 2.6558E-08 
114 +10nMCRH(22h) 2.507 1.4761E-05 6.7095E-07 1.0171E-07 
114 +36nMCRH(22h) 1.760 1.1915E-05 5.4157E-07 -2.7672E-08 
114 +54nMCRH(22h) 0.973 1.1706E-05 5.3207E-07 -3.7173E-08 
Tab.5.5: Cell- and ACTH response through different CRH concentrations (part II) 
 
Fig. 5.4: Extracellular ACTH secretion rate through different CRH concentrations 
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Fig. 5.5: Comparison of cell- (A) and ACTH concentrations (B) through different CRH concentrations 
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5.5 Real-time ACTH response to CRH at two time windows 
Real-time measurements were performed within two time borders: One at the crossover 
of the exponential to the stationary phase (after 92 hours of incubation time) and the 
other at the end of the stationary phase (after 114 hours). Fig. 5.6 (data from Tab.5.6, 
Tab.5.7) illustrates the rapid and highest ACTH response per cell to a stress signal within a 
minute! The secretion of ACTH molecules into the extracellular space is flattened in the 
next two hours nearly to the basal rate. These observations are consistent with previous 
reports showing the glucocorticoid-induced inhibition of ACTH secretion [4][56] and thus 
indicating similar pathways for stimulating and inhibiting factors of ACTH secretion. 
However, there is evidence of the activation of a non-genomic pathway by specific CRH 
receptors complexes [23], appearing immediately in a few seconds and minutes after CRH 
binding to its membrane receptor. ACTH is transported in clathrin-coated vesicles [30][36] 
via post-Golgi vesicle trafficking on microtubules to the proximity of the release site. Then 
vesicles are loaded onto an actin/myosin system for distal transport through the actin 
cortex to just below the plasma membrane, where vesicle tethering or docking to the 
membrane occurs [24]. These docked vesicles form the releasable pool, which is ready for 
takeoff. Stimulated by a stress signal (e.g. CRH), the docked vesicles fuse with the plasma 
membrane and ACTH molecules are released into the extracellular space.  
Time delays in the secretion of ACTH-vesicles, which are tethered to the membrane, as a 
result of a longer transport route to the membrane are comprehensible and are mainly 
included in the measured ACTH levels after 15 minutes CRH incubation time. 
Furthermore we found out that the ACTH response to the same CRH signal leads to a 
delay after 114 hours total incubation time compared to the one after 92 hours, which 
could be directly linked to the worsen cell growing conditions due to the loss of nutrients 
in the medium and the shutdown of the cytoplasmic machinery of cells in the battle 
against apoptosis. 
Additionally, the latter, long-term effect of CRH is known to involve an increase in ACTH 
via the translation of the POMC mRNA [23]. This pathway is necessary for ‘filling up’ the 
pool of released ACTH vesicles beneath the plasma membrane as well. It is not clear up to 
now at which time the systemic switch from the non-genomic to the genomic pathway 
occurs in vitro, but this will be the goal for further studies in the future. 
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[h]  [cells/ml] [cells/ml] [nM] [nM] 
92  154390 32039 14.391 0.660 
 +10nMCRH(1min) 154390 32039 14.787 1.024 
 +10nMCRH(15min) 154390 32039 15.124 0.677 
 +10nMCRH(30min) 154390 32039 15.429 1.060 
 +10nMCRH(1h) 154390 32039 15.532 0.608 
 +10nMCRH(2h) 154390 32039 16.151 1.056 
116 +10nMCRH(22h) 324219 19532 16.898 1.065 
      
114  205163 35327 15.027 0.666 
 +10nMCRH(1min) 205163 35327 15.167 0.467 
 +10nMCRH(15min) 205163 35327 15.621 1.462 
 +10nMCRH(30min) 205163 35327 15.683 0.561 
 +10nMCRH(1h) 205163 35327 15.869 0.882 
 +10nMCRH(2h) 205163 35327 17.152 1.110 
136 +10nMCRH(22h) 425000 44375 18.090 0.763 
Tab.5.6: ACTH response to CRH at different incubation times (after 92 h and 114 h, part I) 
time 
 ACTH 
after  CRH 
incubation 
ACTH/cell ACTH rate 
[h]  [nM] [nM.ml/cell] [nM.ml.h/cell] 
92  0    
 +10nMCRH(1min) 0.396 2.5638E-06 1.5383E-04 
 +10nMCRH(15min) 0.733 2.1828E-06 8.7312E-06 
 +10nMCRH(30min) 1.038 1.9769E-06 3.9537E-06 
 +10nMCRH(1h) 1.141 6.6925E-07 6.6925E-07 
 +10nMCRH(2h) 1.760 4.0052E-06 2.0026E-06 
116 +10nMCRH(22h) 2.507 4.3993E-06 1.8330E-07 
     
114  0    
 +10nMCRH(1min) 0.140 6.8184E-07 4.0910E-05 
 +10nMCRH(15min) 0.595 2.2160E-06 8.8639E-06 
 +10nMCRH(30min) 0.657 3.0218E-07 6.0435E-07 
 +10nMCRH(1h) 0.843 9.0653E-07 9.0653E-07 
 +10nMCRH(2h) 2.125 6.2527E-06 3.1264E-06 
136 +10nMCRH(22h) 3.063 4.2663E-06 1.7776E-07 
Tab.5.7: ACTH response to CRH at different incubation times (after 92 h and 114 h, part II) 






Fig. 5.6: Comparison of total ACTH response (A) and ACTH output rate (B) at two time windows  
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6 Appendix 
6.1 Absorption spectra of the labelled antibody 
λ A λ A λ A λ A λ A 
[nm]  [nm]  [nm]  [nm]  [nM]  
250 0.0539 310 0.0103 370 0.0013 430 0.0012 490 0.0107 
252 0.0556 312 0.0092 372 0.0023 432 0.0012 492 0.0107 
254 0.0549 314 0.0092 374 0.0029 434 0.0018 494 0.0105 
256 0.0557 316 0.0082 376 0.0019 436 0.0011 496 0.0102 
258 0.0569 318 0.0070 378 0.0029 438 0.0011 498 0.0100 
260 0.0582 320 0.0069 380 0.0013 440 0.0010 500 0.0100 
262 0.0581 322 0.0057 382 0.0002 442 0.0017 502 0.0090 
264 0.0581 324 0.0078 384 0.0011 444 0.0017 504 0.0077 
266 0.0600 326 0.0045 386 0.0001 446 0.0013 506 0.0065 
268 0.0604 328 0.0030 388 0.0002 448 0.0017 508 0.0058 
270 0.0600 330 0.0046 390 0.0004 450 0.0019 510 0.0046 
272 0.0589 332 0.0040 392 0.0017 452 0.0019 512 0.0039 
274 0.0571 334 0.0066 394 0.0014 454 0.0021 514 0.0028 
276 0.0562 336 0.0043 396 0.0014 456 0.0023 516 0.0018 
278 0.0539 338 0.0035 398 0.0030 458 0.0032 518 0.0013 
280 0.0526 340 0.0032 400 0.0011 460 0.0031 520 0.0012 
282 0.0502 342 0.0054 402 0.0005 462 0.0037 522 0.0008 
284 0.0475 344 0.0036 404 0.0010 464 0.0039 524 0.0002 
286 0.0426 346 0.0027 406 0.0014 466 0.0043 526 0 
288 0.0388 348 0.0055 408 0.0017 468 0.0038 528 0 
290 0.0363 350 0.0047 410 0.0012 470 0.0046 530 0.0001 
292 0.0325 352 0.0037 412 0.0009 472 0.0061 532 0.0002 
294 0.0296 354 0.0029 414 0.0006 474 0.0058 534 0.0002 
296 0.0263 356 0.0029 416 0.0015 476 0.0058 536 0.0001 
298 0.0214 358 0.0024 418 0.0018 478 0.0072 538 0 
300 0.0197 360 0.0032 420 0.0010 480 0.0072 540 0.0001 
302 0.0167 362 0.0033 422 0.0023 482 0.0083 542 0.0001 
304 0.0155 364 0.0028 424 0.0012 484 0.0080 544 0 
306 0.0135 366 0.0030 426 0.0019 486 0.0096 546 0.0002 
308 0.0128 368 0.0018 428 0.0006 488 0.0103 548 0.0004 
Tab.6.1: Absorption spectra of DyLight488 
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6.2 AtT-20 counts 
Basically, all cell numbers were counted with a Bürker-Türk counting chamber (for further 
information see Fig. 4.5) and the total cell population was deduced from that counts 
following the formula in chapter 4.3. Each sample was incubated under the same 
conditions (37°C, 5% CO2, 95% humidity) and prepared for cell counting in the same way 
(see chapter 4.2.4) to ensure reproducible and comparable results. 
Incub.  
time 
    
Cell counts per 16 squares 
total 
polulation 
+/-   
 

















































































































































































































































































126 14 14 9 11 15 12 12    194196 25511 
138 12 11 14 9 12 8 11 13 9  171875 24305 
Tab.6.2: Basal population of AtT-20 cells 
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Incub.  
time 
 Cell counts 
per 16 squares 
total 
polulation 
+/-   
 
[h]         [cells/ml] [cells/ml] 
















114 + 10nM CRH  (24h) 23 20 19 21    324219 19532 















114 + 54nM CRH (24h) 17 14 13 17 15   237500 22500 
































Tab.6.3: Effect of extracellular stress signals to the population of AtT-20 cells 
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6.3 2-component fits 
For calculating the exact ACTH concentration the diffusion time of the first component 
was fixed to computationally eliminate the particle numbers of the unbound fluorescent 
antibodies (chapter 4.4.2). Subsequently the correction factor (CFFCS) had to be taken into 
account for all ACTH concentrations obtained from computationally fits of FCS data. 
Tab.6.4 summarizes the calculated ACTH concentrations obtained from the 2-component 
fits, which are listed on the following pages, and the actual concentration in consideration 










[h]  [nM] [nM] [nM] [nM] 
20 Basal 3.931 0.234 6.249 0.372 
40 Basal 7.079 0.435 11.253 0.691 
65 Basal 8.608 0.608 13.684 0.967 
92 Basal 9.053 0.415 14.391 0.660 
114 Basal 9.453 0.419 15.027 0.666 
138 basal 9.867 0.333 15.685 0.529 
92 + 10nM CRH (1min) 9.302 0.644 14.787 1.024 
92 + 10nM CRH (15min) 9.514 0.426 15.124 0.677 
92 + 10nM CRH (30min) 9.706 0.667 15.429 1.060 
92 + 10nM CRH (1h) 9.771 0.382 15.532 0.608 
92 + 10nM CRH (2h) 10.160 0.665 16.151 1.056 
114 + 10nM CRH (22h) 10.630 0.670 16.898 1.065 
114 + 10nM CRH (1min) 9.541 0.294 15.167 0.467 
114 + 10nM CRH (15min) 9.827 0.920 15.621 1.462 
114 + 10nM CRH (30min) 9.866 0.353 15.683 0.561 
114 + 10nM CRH (1h) 9.983 0.555 15.869 0.882 
114 + 10nM CRH (2h) 10.790 0.698 17.152 1.110 
136 + 10nM CRH (22h) 11.380 0.480 18.090 0.763 
114 +5nMCRH(24h) 10.55 0.576 16.771 0.916 
114 +10nMCRH(24h) 10.63 0.670 16.898 1.065 
114 +36nMCRH(24h) 10.16 0.569 16.151 0.904 
114 +54nMCRH(24h) 9.665 0.874 15.364 1.389 
Tab.6.4: Summarized ACTH concentrations (including correction factor) 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 5 4.003E-09 1.745E-03 0.532 2.464E-08 2.300E-04 3.275 7.400E-06 0.28 2.820E-03 
 6 3.760E-09 2.089E-03 0.499 2.504E-08 2.300E-04 3.328 7.400E-06 0.30 1.940E-03 
 7 3.778E-09 2.287E-03 0.502 2.412E-08 2.300E-04 3.206 8.100E-06 0.27 1.250E-03 
 8 3.914E-09 1.547E-03 0.520 2.521E-08 2.300E-04 3.350 8.400E-06 0.29 2.030E-03 
 10 3.833E-09 2.162E-03 0.509 2.421E-08 2.300E-04 3.218 7.000E-06 0.29 2.240E-03 
 11 3.729E-09 1.477E-03 0.496 2.438E-08 2.300E-04 3.240 7.900E-06 0.28 1.440E-03 
 12 3.971E-09 1.727E-03 0.528 2.435E-08 2.300E-04 3.236 8.800E-06 0.28 2.100E-03 
 14 3.366E-09 2.098E-03 0.447 2.439E-08 2.300E-04 3.242 7.000E-06 0.28 2.440E-03 
 16 3.560E-09 1.786E-03 0.473 2.435E-08 2.300E-04 3.235 6.500E-06 0.28 2.250E-03 
 17 4.434E-09 1.562E-03 0.589 2.462E-08 2.300E-04 3.272 9.700E-06 0.28 1.970E-03 
 18 3.388E-09 1.836E-03 0.450 2.588E-08 2.300E-04 3.439 7.700E-06 0.29 1.370E-03 
 21 3.391E-09 2.077E-03 0.451 2.484E-08 2.300E-04 3.300 7.900E-06 0.27 2.350E-03 
 23 3.637E-09 2.300E-03 0.483 2.486E-08 2.300E-04 3.304 6.500E-06 0.30 2.110E-03 
 27 4.309E-09 1.960E-03 0.573 2.368E-08 2.300E-04 3.147 7.400E-06 0.28 1.790E-03 
 29 3.739E-09 1.833E-03 0.497 2.630E-08 2.300E-04 3.495 9.000E-06 0.30 2.030E-03 
 33 4.154E-09 1.672E-03 0.552 2.352E-08 2.300E-04 3.125 8.100E-06 0.29 1.620E-03 
 34 4.488E-09 1.511E-03 0.596 2.479E-08 2.300E-04 3.295 9.000E-06 0.28 2.060E-03 
 36 4.396E-09 1.628E-03 0.584 2.433E-08 2.300E-04 3.234 8.100E-06 0.28 1.770E-03 
 38 3.799E-09 1.760E-03 0.505 2.537E-08 2.300E-04 3.372 7.100E-06 0.29 2.370E-03 
 40 4.030E-09 2.027E-03 0.536 2.415E-08 2.300E-04 3.209 7.500E-06 0.29 1.670E-03 
 41 3.667E-09 2.211E-03 0.487 2.561E-08 2.300E-04 3.404 7.900E-06 0.28 2.050E-03 
 46 3.998E-09 1.978E-03 0.531 2.481E-08 2.300E-04 3.297 7.400E-06 0.29 2.170E-03 
 47 4.249E-09 1.751E-03 0.565 2.307E-08 2.300E-04 3.065 7.400E-06 0.26 2.810E-03 
 48 4.339E-09 2.302E-03 0.577 2.417E-08 2.300E-04 3.212 9.400E-06 0.28 1.570E-03 
 49 4.364E-09 2.116E-03 0.580 2.413E-08 2.300E-04 3.207 7.300E-06 0.29 2.280E-03 
 50 4.005E-09 1.776E-03 0.532 2.353E-08 2.300E-04 3.127 7.300E-06 0.27 2.460E-03 
 51 3.686E-09 2.019E-03 0.490 2.518E-08 2.300E-04 3.346 7.200E-06 0.30 1.590E-03 
 52 4.155E-09 2.052E-03 0.552 2.391E-08 2.300E-04 3.177 7.900E-06 0.28 1.490E-03 
 53 3.743E-09 1.655E-03 0.498 2.438E-08 2.300E-04 3.239 7.800E-06 0.28 1.900E-03 
 54 3.848E-09 1.346E-03 0.511 2.545E-08 2.300E-04 3.382 8.900E-06 0.27 2.090E-03 
 55 4.146E-09 1.824E-03 0.551 2.450E-08 2.300E-04 3.256 7.800E-06 0.28 1.560E-03 
 56 4.002E-09 1.525E-03 0.532 2.417E-08 2.300E-04 3.212 8.900E-06 0.27 2.180E-03 
 57 4.038E-09 2.268E-03 0.537 2.489E-08 2.300E-04 3.307 7.700E-06 0.29 2.090E-03 
 58 3.795E-09 1.725E-03 0.505 2.445E-08 2.300E-04 3.249 8.100E-06 0.27 2.090E-03 
 59 3.792E-09 1.424E-03 0.504 2.457E-08 2.300E-04 3.266 9.000E-06 0.26 2.140E-03 
 x� 3.931E-09 1.840E-03 0.522 
      
 x� ± 2.341E-10 2.351E-04 0.031 
 
 
Tab.6.5: 2-component fit for calculating basal ACTH after 20 h 
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Fig. 6.1: Concdiff-plot of 2-component fit after 20 h total incubation time 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 3 6.769E-09 1.294E-03 0.899 2.122E-08 1.970E-04 2.820 6.200E-06 0.20 1.580E-03 
 11 7.488E-09 1.319E-03 0.995 2.115E-08 1.970E-04 2.811 6.300E-06 0.20 1.200E-03 
 12 7.791E-09 9.796E-04 1.035 2.001E-08 1.970E-04 2.659 6.100E-06 0.21 1.690E-03 
 14 7.505E-09 1.327E-03 0.997 2.020E-08 1.970E-04 2.684 6.400E-06 0.20 1.060E-03 
 16 7.748E-09 1.111E-03 1.030 1.943E-08 1.970E-04 2.582 5.500E-06 0.21 1.820E-03 
 25 6.735E-09 1.184E-03 0.895 2.134E-08 1.970E-04 2.836 6.700E-06 0.19 8.710E-04 
 27 7.511E-09 1.043E-03 0.998 2.012E-08 1.970E-04 2.673 6.300E-06 0.20 1.110E-03 
 31 6.946E-09 1.325E-03 0.923 2.114E-08 1.970E-04 2.809 5.300E-06 0.22 1.340E-03 
 32 7.768E-09 1.051E-03 1.032 2.070E-08 1.970E-04 2.751 6.900E-06 0.21 1.250E-03 
 33 7.088E-09 1.345E-03 0.942 2.090E-08 1.970E-04 2.777 5.100E-06 0.23 1.370E-03 
 34 7.979E-09 1.028E-03 1.060 2.031E-08 1.970E-04 2.699 6.400E-06 0.22 1.260E-03 
 36 7.038E-09 1.219E-03 0.935 2.092E-08 1.970E-04 2.779 5.200E-06 0.22 1.100E-03 
 41 7.390E-09 1.006E-03 0.982 2.000E-08 1.970E-04 2.658 4.700E-06 0.23 1.190E-03 
 45 6.816E-09 9.811E-04 0.906 2.072E-08 1.970E-04 2.754 4.800E-06 0.21 1.350E-03 
 47 7.628E-09 1.276E-03 1.014 2.080E-08 1.970E-04 2.764 5.800E-06 0.21 1.360E-03 
 55 6.299E-09 1.194E-03 0.837 2.083E-08 1.970E-04 2.768 4.400E-06 0.21 1.520E-03 
 59 7.722E-09 1.110E-03 1.026 1.990E-08 1.970E-04 2.644 6.800E-06 0.20 1.430E-03 
 60 7.562E-09 1.028E-03 1.005 2.021E-08 1.970E-04 2.686 6.500E-06 0.20 1.540E-03 
 61 7.999E-09 1.042E-03 1.063 1.917E-08 1.970E-04 2.547 6.400E-06 0.19 1.250E-03 
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 65 8.066E-09 9.614E-04 1.072 1.910E-08 1.970E-04 2.539 5.000E-06 0.21 1.320E-03 
 67 7.930E-09 9.197E-04 1.054 1.962E-08 1.970E-04 2.607 5.500E-06 0.20 1.360E-03 
 76 7.724E-09 1.083E-03 1.026 2.040E-08 1.970E-04 2.711 5.800E-06 0.23 1.100E-03 
 80 7.206E-09 1.483E-03 0.958 2.168E-08 1.970E-04 2.881 6.400E-06 0.22 1.010E-03 
 81 7.610E-09 1.256E-03 1.011 2.124E-08 1.970E-04 2.823 6.100E-06 0.23 1.100E-03 
 82 6.541E-09 1.708E-03 0.869 2.183E-08 1.970E-04 2.901 5.100E-06 0.23 2.050E-03 
 83 6.444E-09 1.562E-03 0.856 2.162E-08 1.970E-04 2.873 5.800E-06 0.22 9.690E-04 
 84 7.248E-09 1.034E-03 0.963 2.076E-08 1.970E-04 2.759 5.100E-06 0.22 1.420E-03 
 87 7.910E-09 1.114E-03 1.051 1.957E-08 1.970E-04 2.600 6.500E-06 0.21 1.310E-03 
 89 6.511E-09 1.668E-03 0.865 2.116E-08 1.970E-04 2.812 4.700E-06 0.22 1.570E-03 
 90 7.009E-09 1.143E-03 0.931 2.195E-08 1.970E-04 2.917 6.700E-06 0.22 1.410E-03 
 93 7.814E-09 1.018E-03 1.038 1.962E-08 1.970E-04 2.607 5.400E-06 0.22 2.390E-03 
 95 6.062E-09 1.474E-03 0.806 2.183E-08 1.970E-04 2.901 5.000E-06 0.21 1.380E-03 
 96 7.070E-09 1.308E-03 0.939 2.122E-08 1.970E-04 2.820 5.600E-06 0.21 1.050E-03 
 99 6.153E-09 1.225E-03 0.818 2.288E-08 1.970E-04 3.040 4.500E-06 0.23 9.810E-04 
 100 6.588E-09 1.110E-03 0.875 2.225E-08 1.970E-04 2.957 5.900E-06 0.23 1.250E-03 
 101 6.554E-09 1.144E-03 0.871 2.181E-08 1.970E-04 2.898 6.100E-06 0.21 1.340E-03 
 102 6.647E-09 1.096E-03 0.883 2.320E-08 1.970E-04 3.083 5.100E-06 0.24 1.170E-03 
 104 6.801E-09 1.295E-03 0.904 2.060E-08 1.970E-04 2.738 5.900E-06 0.20 1.430E-03 
 105 6.326E-09 1.173E-03 0.841 2.236E-08 1.970E-04 2.971 5.900E-06 0.21 1.000E-03 
 106 6.353E-09 1.509E-03 0.844 2.292E-08 1.970E-04 3.046 5.800E-06 0.21 1.300E-03 
 109 7.237E-09 1.244E-03 0.962 2.141E-08 1.970E-04 2.845 5.800E-06 0.23 1.570E-03 
 110 7.340E-09 1.069E-03 0.975 2.154E-08 1.970E-04 2.863 6.300E-06 0.21 1.050E-03 
 111 7.320E-09 1.243E-03 0.973 2.063E-08 1.970E-04 2.741 5.600E-06 0.23 1.480E-03 
 112 7.593E-09 1.318E-03 1.009 2.154E-08 1.970E-04 2.862 6.500E-06 0.22 1.270E-03 
 119 6.749E-09 1.529E-03 0.897 2.212E-08 1.970E-04 2.940 6.000E-06 0.22 1.240E-03 
 120 7.513E-09 1.203E-03 0.998 2.108E-08 1.970E-04 2.802 6.800E-06 0.21 1.050E-03 
 124 7.523E-09 1.148E-03 0.999 2.169E-08 1.970E-04 2.882 6.400E-06 0.23 1.380E-03 
 125 6.601E-09 1.303E-03 0.877 2.101E-08 1.970E-04 2.792 4.700E-06 0.22 1.690E-03 
 126 6.162E-09 1.684E-03 0.819 2.304E-08 1.970E-04 3.061 6.900E-06 0.21 1.150E-03 
 128 7.336E-09 1.133E-03 0.975 2.172E-08 1.970E-04 2.886 6.900E-06 0.21 1.120E-03 
 132 6.453E-09 1.217E-03 0.857 2.193E-08 1.970E-04 2.915 5.900E-06 0.22 1.150E-03 
 133 7.205E-09 1.197E-03 0.958 2.136E-08 1.970E-04 2.839 6.600E-06 0.21 1.310E-03 
 136 6.271E-09 1.436E-03 0.833 2.217E-08 1.970E-04 2.946 5.600E-06 0.22 1.540E-03 
 137 7.151E-09 1.359E-03 0.950 2.084E-08 1.970E-04 2.770 5.100E-06 0.22 1.630E-03 
 138 6.265E-09 1.512E-03 0.832 2.227E-08 1.970E-04 2.959 6.000E-06 0.22 1.090E-03 
 142 6.673E-09 1.390E-03 0.887 2.191E-08 1.970E-04 2.911 5.900E-06 0.20 1.570E-03 
 145 6.945E-09 1.158E-03 0.923 2.124E-08 1.970E-04 2.823 4.800E-06 0.23 2.020E-03 
 146 6.111E-09 1.274E-03 0.812 2.250E-08 1.970E-04 2.990 5.100E-06 0.22 1.630E-03 
 149 6.224E-09 1.515E-03 0.827 2.310E-08 1.970E-04 3.070 6.600E-06 0.21 9.090E-04 
 153 6.466E-09 1.239E-03 0.859 2.206E-08 1.970E-04 2.932 5.400E-06 0.22 1.100E-03 
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 154 6.798E-09 1.322E-03 0.903 2.194E-08 1.970E-04 2.916 5.200E-06 0.23 1.740E-03 
122 2 6.858E-09 1.020E-03 0.911 1.950E-08 2.060E-04 2.591 5.000E-06 0.18 2.260E-03 
 5 6.970E-09 9.817E-04 0.926 1.994E-08 2.060E-04 2.650 6.300E-06 0.18 1.420E-03 
 6 6.686E-09 1.161E-03 0.889 2.058E-08 2.060E-04 2.735 3.700E-06 0.23 3.170E-03 
 11 7.354E-09 1.162E-03 0.977 1.845E-08 2.060E-04 2.451 5.900E-06 0.19 1.660E-03 
 12 6.962E-09 1.180E-03 0.925 1.980E-08 2.060E-04 2.632 5.900E-06 0.18 1.770E-03 
 14 7.302E-09 1.088E-03 0.970 1.825E-08 2.060E-04 2.426 5.600E-06 0.18 1.950E-03 
 17 7.126E-09 1.130E-03 0.947 1.985E-08 2.060E-04 2.638 7.200E-06 0.19 2.110E-03 
 21 7.454E-09 1.193E-03 0.991 1.978E-08 2.060E-04 2.628 5.900E-06 0.19 2.070E-03 
 22 7.436E-09 1.194E-03 0.988 1.951E-08 2.060E-04 2.593 4.700E-06 0.20 1.710E-03 
 33 7.065E-09 1.154E-03 0.939 2.048E-08 2.060E-04 2.722 7.000E-06 0.18 1.650E-03 
 35 7.138E-09 1.035E-03 0.949 2.036E-08 2.060E-04 2.706 5.000E-06 0.21 2.590E-03 
 36 6.913E-09 1.249E-03 0.919 1.970E-08 2.060E-04 2.618 5.700E-06 0.20 1.800E-03 
 46 6.941E-09 1.154E-03 0.922 1.987E-08 2.060E-04 2.640 5.500E-06 0.20 2.050E-03 
 48 6.794E-09 1.319E-03 0.903 1.897E-08 2.060E-04 2.521 5.400E-06 0.19 1.800E-03 
 50 6.997E-09 1.174E-03 0.930 1.950E-08 2.060E-04 2.591 5.800E-06 0.18 1.720E-03 
 51 7.576E-09 1.272E-03 1.007 1.929E-08 2.060E-04 2.563 7.200E-06 0.18 1.820E-03 
 54 7.043E-09 1.185E-03 0.936 2.047E-08 2.060E-04 2.720 5.100E-06 0.20 1.550E-03 
 59 7.097E-09 1.385E-03 0.943 2.008E-08 2.060E-04 2.669 7.100E-06 0.19 1.170E-03 
 60 7.613E-09 1.261E-03 1.012 1.947E-08 2.060E-04 2.587 6.600E-06 0.19 1.100E-03 
 x� 7.079E-09 1.220E-03 0.941 
      
 x� ± 4.349E-10 1.365E-04 0.058 
 
 
Tab.6.6: 2-component fit for calculating basal ACTH after 40 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 2 9.281E-09 1.432E-03 1.233 1.876E-08 2.290E-04 2.493 5.300E-06 0.17 1.490E-03 
 3 9.313E-09 9.602E-04 1.238 1.998E-08 2.290E-04 2.655 5.600E-06 0.17 1.810E-03 
 5 9.515E-09 9.703E-04 1.265 1.798E-08 2.290E-04 2.389 5.500E-06 0.17 2.080E-03 
 7 8.268E-09 1.358E-03 1.099 1.926E-08 2.290E-04 2.560 4.200E-06 0.17 1.190E-03 
 9 9.278E-09 1.144E-03 1.233 1.752E-08 2.290E-04 2.328 4.300E-06 0.19 1.260E-03 
 14 8.600E-09 1.084E-03 1.143 1.924E-08 2.290E-04 2.557 6.700E-06 0.15 1.060E-03 
 15 9.092E-09 1.093E-03 1.208 1.749E-08 2.290E-04 2.324 3.400E-06 0.18 1.570E-03 
 18 7.582E-09 1.274E-03 1.008 1.923E-08 2.290E-04 2.556 3.600E-06 0.19 1.590E-03 
 19 7.995E-09 1.062E-03 1.062 1.922E-08 2.290E-04 2.554 3.900E-06 0.17 1.260E-03 
 20 9.823E-09 9.843E-04 1.305 1.700E-08 2.290E-04 2.260 4.900E-06 0.18 1.460E-03 
 25 7.781E-09 1.246E-03 1.034 1.910E-08 2.290E-04 2.538 5.000E-06 0.17 1.160E-03 
 26 7.541E-09 1.284E-03 1.002 1.862E-08 2.290E-04 2.474 4.700E-06 0.15 1.590E-03 
 30 8.658E-09 1.047E-03 1.151 1.873E-08 2.290E-04 2.489 5.000E-06 0.15 2.330E-03 
 31 9.244E-09 1.184E-03 1.228 1.756E-08 2.290E-04 2.334 6.200E-06 0.17 1.170E-03 
 38 9.084E-09 9.617E-04 1.207 1.694E-08 2.290E-04 2.251 5.300E-06 0.15 2.080E-03 
 40 8.201E-09 1.206E-03 1.090 1.807E-08 2.290E-04 2.401 5.900E-06 0.16 1.860E-03 
 42 9.015E-09 1.268E-03 1.198 1.856E-08 2.290E-04 2.467 5.300E-06 0.17 1.530E-03 
 43 9.792E-09 8.690E-04 1.301 1.797E-08 2.290E-04 2.388 6.400E-06 0.16 1.290E-03 
 45 7.906E-09 9.831E-04 1.051 1.871E-08 2.290E-04 2.487 4.000E-06 0.16 1.030E-03 
 47 9.150E-09 1.015E-03 1.216 1.844E-08 2.290E-04 2.450 5.300E-06 0.17 1.460E-03 
 49 8.906E-09 9.489E-04 1.184 1.755E-08 2.290E-04 2.333 5.000E-06 0.17 1.620E-03 
 51 8.041E-09 1.150E-03 1.069 1.882E-08 2.290E-04 2.501 5.200E-06 0.16 1.720E-03 
 56 8.385E-09 1.176E-03 1.114 1.757E-08 2.290E-04 2.335 5.000E-06 0.16 1.650E-03 
 58 8.284E-09 1.194E-03 1.101 1.874E-08 2.290E-04 2.491 4.400E-06 0.17 2.160E-03 
146 1 8.524E-09 1.107E-03 1.133 1.930E-08 2.290E-04 2.565 3.500E-06 0.20 1.430E-03 
 3 9.259E-09 1.180E-03 1.230 1.892E-08 2.290E-04 2.515 4.800E-06 0.18 2.260E-03 
 5 7.885E-09 1.423E-03 1.048 1.978E-08 2.290E-04 2.629 3.900E-06 0.19 1.380E-03 
 6 8.125E-09 1.249E-03 1.080 1.961E-08 2.290E-04 2.606 4.300E-06 0.17 1.800E-03 
 11 7.016E-09 1.310E-03 0.932 2.052E-08 2.290E-04 2.727 4.300E-06 0.16 1.800E-03 
 13 8.829E-09 1.116E-03 1.173 1.896E-08 2.290E-04 2.519 5.100E-06 0.17 1.850E-03 
 18 8.528E-09 1.047E-03 1.133 2.010E-08 2.290E-04 2.671 5.600E-06 0.16 2.340E-03 
 20 8.899E-09 1.172E-03 1.183 1.907E-08 2.290E-04 2.534 6.200E-06 0.19 2.360E-03 
 22 8.381E-09 1.206E-03 1.114 1.965E-08 2.290E-04 2.611 4.300E-06 0.18 1.920E-03 
 23 9.478E-09 9.721E-04 1.260 1.898E-08 2.290E-04 2.523 6.000E-06 0.18 1.570E-03 
 25 9.223E-09 9.822E-04 1.226 1.856E-08 2.290E-04 2.467 3.900E-06 0.18 1.590E-03 
 28 9.854E-09 9.405E-04 1.309 1.828E-08 2.290E-04 2.429 5.600E-06 0.16 1.640E-03 
 29 8.156E-09 1.257E-03 1.084 2.069E-08 2.290E-04 2.750 5.900E-06 0.16 1.890E-03 
 30 8.176E-09 1.312E-03 1.086 1.984E-08 2.290E-04 2.637 5.800E-06 0.17 1.640E-03 
 31 8.916E-09 1.301E-03 1.185 1.942E-08 2.290E-04 2.581 5.900E-06 0.17 1.950E-03 
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 32 8.227E-09 1.253E-03 1.093 2.061E-08 2.290E-04 2.739 7.800E-06 0.16 2.300E-03 
 34 9.101E-09 1.106E-03 1.209 1.947E-08 2.290E-04 2.588 6.300E-06 0.19 1.320E-03 
 35 7.662E-09 1.396E-03 1.018 1.976E-08 2.290E-04 2.626 4.300E-06 0.19 1.860E-03 
 36 9.662E-09 9.532E-04 1.284 1.984E-08 2.290E-04 2.637 6.400E-06 0.18 1.410E-03 
 37 7.538E-09 1.276E-03 1.002 2.060E-08 2.290E-04 2.738 5.300E-06 0.16 1.780E-03 
 38 9.421E-09 1.012E-03 1.252 1.836E-08 2.290E-04 2.441 5.100E-06 0.16 1.430E-03 
 41 7.871E-09 1.365E-03 1.046 2.046E-08 2.290E-04 2.718 5.000E-06 0.17 1.490E-03 
 43 8.066E-09 1.004E-03 1.072 2.081E-08 2.290E-04 2.766 4.100E-06 0.18 1.060E-03 
 45 9.369E-09 8.927E-04 1.245 1.895E-08 2.290E-04 2.518 5.300E-06 0.17 2.060E-03 
 47 7.639E-09 1.511E-03 1.015 1.950E-08 2.290E-04 2.592 5.500E-06 0.16 3.130E-03 
 48 8.326E-09 1.178E-03 1.106 1.889E-08 2.290E-04 2.510 4.100E-06 0.16 1.880E-03 
 49 7.872E-09 1.274E-03 1.046 2.004E-08 2.290E-04 2.664 6.300E-06 0.17 1.360E-03 
 51 9.629E-09 1.193E-03 1.280 1.875E-08 2.290E-04 2.491 6.600E-06 0.17 1.380E-03 
 52 8.443E-09 1.182E-03 1.122 2.063E-08 2.290E-04 2.742 6.600E-06 0.17 1.200E-03 
 55 8.963E-09 1.148E-03 1.191 1.826E-08 2.290E-04 2.427 4.700E-06 0.16 2.120E-03 
 56 9.065E-09 9.469E-04 1.205 1.849E-08 2.290E-04 2.457 7.300E-06 0.15 1.430E-03 
 57 8.386E-09 1.141E-03 1.114 1.932E-08 2.290E-04 2.567 4.700E-06 0.18 1.970E-03 
 59 7.192E-09 1.576E-03 0.956 2.080E-08 2.290E-04 2.764 4.700E-06 0.15 1.340E-03 
 60 8.834E-09 1.302E-03 1.174 1.938E-08 2.290E-04 2.575 6.400E-06 0.16 1.450E-03 
 x� 8.608E-09 1.158E-03 1.144 
      
 x� ± 6.081E-10 1.307E-04 0.081 
 
 
Tab.6.7: 2-component fit for calculating basal ACTH after 65 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 9.104E-09 8.932E-04 1.210 1.800E-08 2.130E-04 2.391 5.100E-06 0.16 2.330E-03 
 4 8.339E-09 1.047E-03 1.108 1.690E-08 2.130E-04 2.246 3.700E-06 0.21 2.350E-03 
 5 8.714E-09 1.098E-03 1.158 1.693E-08 2.130E-04 2.250 7.500E-06 0.17 1.800E-03 
 8 8.070E-09 1.167E-03 1.072 1.746E-08 2.130E-04 2.321 6.000E-06 0.18 2.880E-03 
 9 1.014E-08 1.043E-03 1.347 1.544E-08 2.130E-04 2.052 9.100E-06 0.17 1.710E-03 
 10 9.313E-09 9.445E-04 1.238 1.572E-08 2.130E-04 2.089 4.900E-06 0.19 1.770E-03 
 11 9.220E-09 8.186E-04 1.225 1.569E-08 2.130E-04 2.085 4.400E-06 0.19 2.920E-03 
 12 9.888E-09 8.579E-04 1.314 1.559E-08 2.130E-04 2.072 4.600E-06 0.20 3.340E-03 
 17 9.492E-09 8.664E-04 1.261 1.575E-08 2.130E-04 2.093 4.600E-06 0.18 1.550E-03 
 19 9.509E-09 8.351E-04 1.264 1.624E-08 2.130E-04 2.159 5.700E-06 0.18 2.050E-03 
 21 8.723E-09 9.681E-04 1.159 1.647E-08 2.130E-04 2.188 5.800E-06 0.17 3.010E-03 
 24 9.792E-09 9.877E-04 1.301 1.553E-08 2.130E-04 2.064 8.500E-06 0.15 1.270E-03 
 25 8.069E-09 9.966E-04 1.072 1.726E-08 2.130E-04 2.293 3.300E-06 0.19 2.050E-03 
 26 9.417E-09 9.117E-04 1.251 1.575E-08 2.130E-04 2.093 7.100E-06 0.17 1.750E-03 
 28 9.287E-09 9.313E-04 1.234 1.570E-08 2.130E-04 2.086 5.800E-06 0.18 1.620E-03 
 36 9.062E-09 8.000E-04 1.204 1.721E-08 2.130E-04 2.287 7.200E-06 0.15 2.690E-03 
 37 8.485E-09 1.028E-03 1.128 1.591E-08 2.130E-04 2.114 4.400E-06 0.18 3.630E-03 
186 1 9.265E-09 1.295E-03 1.231 2.415E-08 2.310E-04 3.209 6.500E-06 0.16 1.190E-03 
 2 8.908E-09 1.410E-03 1.184 2.253E-08 2.310E-04 2.994 5.100E-06 0.19 1.320E-03 
 3 8.551E-09 1.303E-03 1.136 2.316E-08 2.310E-04 3.077 4.400E-06 0.21 1.870E-03 
 6 9.322E-09 1.221E-03 1.239 2.194E-08 2.310E-04 2.916 7.500E-06 0.16 1.590E-03 
 7 8.683E-09 1.093E-03 1.154 2.280E-08 2.310E-04 3.029 6.300E-06 0.18 1.810E-03 
 8 9.009E-09 1.335E-03 1.197 2.188E-08 2.310E-04 2.908 8.400E-06 0.17 1.970E-03 
 10 9.892E-09 9.819E-04 1.315 2.219E-08 2.310E-04 2.948 7.700E-06 0.18 2.700E-03 
 14 8.981E-09 1.110E-03 1.193 2.231E-08 2.310E-04 2.965 5.100E-06 0.19 1.420E-03 
 17 9.445E-09 1.118E-03 1.255 2.141E-08 2.310E-04 2.845 8.900E-06 0.17 1.240E-03 
 18 8.266E-09 1.476E-03 1.099 2.378E-08 2.310E-04 3.160 4.900E-06 0.19 3.390E-03 
 23 8.243E-09 1.353E-03 1.095 2.213E-08 2.310E-04 2.940 6.100E-06 0.16 2.840E-03 
 26 9.086E-09 1.320E-03 1.207 2.179E-08 2.310E-04 2.896 5.300E-06 0.19 2.070E-03 
 28 9.095E-09 1.088E-03 1.209 2.182E-08 2.310E-04 2.899 5.600E-06 0.18 2.260E-03 
 30 8.985E-09 1.024E-03 1.194 2.136E-08 2.310E-04 2.838 6.600E-06 0.17 1.570E-03 
 31 9.102E-09 1.236E-03 1.210 2.095E-08 2.310E-04 2.784 6.700E-06 0.16 1.990E-03 
 33 9.454E-09 1.223E-03 1.256 2.139E-08 2.310E-04 2.843 6.700E-06 0.17 1.740E-03 
 36 9.443E-09 8.606E-04 1.255 2.191E-08 2.310E-04 2.912 6.300E-06 0.18 1.750E-03 
 37 8.515E-09 1.322E-03 1.132 2.271E-08 2.310E-04 3.018 6.700E-06 0.18 1.650E-03 
 x� 9.053E-09 1.085E-03 1.203       
 x� ± 4.149E-10 1.559E-04 0.055  
 
Tab.6.8: 2-component fit for calculating basal ACTH after 92 h 
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Fig. 6.4: Concdiff-plot of 2-component fit after 92 h total incubation time 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 4 9.786E-09 1.106E-03 1.300 2.074E-08 2.140E-04 2.756 7.600E-06 0.16 2.040E-03 
 5 9.455E-09 1.164E-03 1.256 1.972E-08 2.140E-04 2.621 6.400E-06 0.16 1.800E-03 
 7 9.774E-09 1.184E-03 1.299 1.923E-08 2.140E-04 2.556 6.900E-06 0.17 1.450E-03 
 14 9.100E-09 1.271E-03 1.209 2.366E-08 2.140E-04 3.144 3.400E-06 0.2 1.530E-03 
 16 9.725E-09 1.037E-03 1.292 2.290E-08 2.140E-04 3.043 2.100E-06 0.24 2.000E-03 
 17 9.106E-09 1.022E-03 1.210 2.006E-08 2.140E-04 2.665 4.100E-06 0.18 2.630E-03 
 20 9.571E-09 1.355E-03 1.272 1.943E-08 2.140E-04 2.582 6.300E-06 0.16 1.730E-03 
 21 9.342E-09 1.583E-03 1.241 2.345E-08 2.140E-04 3.116 3.100E-06 0.2 1.480E-03 
 23 9.457E-09 1.295E-03 1.257 2.388E-08 2.140E-04 3.174 4.700E-06 0.15 1.660E-03 
 24 9.354E-09 1.167E-03 1.243 2.457E-08 2.140E-04 3.266 5.100E-06 0.17 1.180E-03 
 27 9.105E-09 1.088E-03 1.210 1.935E-08 2.140E-04 2.572 4.200E-06 0.19 2.340E-03 
 32 9.361E-09 1.424E-03 1.244 2.476E-08 2.140E-04 3.290 6.200E-06 0.14 2.570E-03 
 33 9.555E-09 1.200E-03 1.270 2.373E-08 2.140E-04 3.154 4.200E-06 0.18 2.400E-03 
 37 9.402E-09 1.104E-03 1.249 2.534E-08 2.140E-04 3.367 4.500E-06 0.18 1.380E-03 
203 4 1.017E-08 9.799E-04 1.351 1.723E-08 2.140E-04 2.289 4.900E-06 0.16 2.000E-03 
 5 9.075E-09 1.125E-03 1.206 1.855E-08 2.140E-04 2.465 5.200E-06 0.19 3.600E-03 
 8 9.573E-09 1.109E-03 1.272 1.733E-08 2.140E-04 2.303 6.400E-06 0.14 2.730E-03 
 10 9.882E-09 1.116E-03 1.313 1.710E-08 2.140E-04 2.272 4.700E-06 0.18 2.800E-03 
 14 9.182E-09 1.178E-03 1.220 1.775E-08 2.140E-04 2.359 7.900E-06 0.14 2.040E-03 
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 20 1.011E-08 9.335E-04 1.343 1.649E-08 2.140E-04 2.191 5.800E-06 0.16 2.010E-03 
 21 9.254E-09 1.086E-03 1.230 1.765E-08 2.140E-04 2.346 3.700E-06 0.19 3.060E-03 
 23 9.034E-09 1.118E-03 1.201 1.831E-08 2.140E-04 2.434 6.100E-06 0.16 2.120E-03 
 28 9.067E-09 1.136E-03 1.205 1.772E-08 2.140E-04 2.355 5.300E-06 0.17 2.130E-03 
 30 9.554E-09 1.109E-03 1.270 1.660E-08 2.140E-04 2.206 3.000E-06 0.19 2.840E-03 
 36 1.015E-08 1.037E-03 1.349 1.582E-08 2.140E-04 2.103 4.400E-06 0.19 2.270E-03 
 38 9.064E-09 1.062E-03 1.204 1.828E-08 2.140E-04 2.429 5.400E-06 0.17 2.530E-03 
 x� 9.453E-09 1.148E-03 1.255 
      
 x�± 4.185E-10 9.916E-05 0.039  
 
Tab.6.9: 2-component fit for calculating basal ACTH after 114 h 
 
Fig. 6.5: Concdiff-plot of 2-component fit after 114 h total incubation time 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 9 9.927E-09 1.021E-03 1.319 2.052E-08 2.370E-04 2.727 4.000E-06 0.17 2.140E-03 
 10 9.955E-09 1.213E-03 1.323 2.312E-08 2.370E-04 3.072 6.400E-06 0.19 2.140E-03 
 13 9.627E-09 1.535E-03 1.279 2.063E-08 2.370E-04 2.741 5.900E-06 0.16 1.780E-03 
 14 9.439E-09 1.417E-03 1.254 2.355E-08 2.370E-04 3.129 1.000E-05 0.16 2.450E-03 
 18 1.006E-08 1.128E-03 1.337 2.154E-08 2.370E-04 2.862 6.200E-06 0.14 1.720E-03 
 18 1.006E-08 1.128E-03 1.337 2.154E-08 2.370E-04 2.862 6.200E-06 0.14 1.720E-03 
 21 9.688E-09 1.249E-03 1.287 2.308E-08 2.370E-04 3.067 1.000E-05 0.15 1.860E-03 
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 23 1.001E-08 1.201E-03 1.330 2.116E-08 2.370E-04 2.812 4.200E-06 0.18 1.890E-03 
 23 1.001E-08 1.201E-03 1.330 2.116E-08 2.370E-04 2.812 4.200E-06 0.18 1.890E-03 
 24 9.696E-09 9.992E-04 1.289 2.121E-08 2.370E-04 2.819 2.900E-06 0.21 1.940E-03 
 29 9.819E-09 1.473E-03 1.305 2.246E-08 2.370E-04 2.985 6.800E-06 0.16 1.840E-03 
 30 1.042E-08 1.372E-03 1.385 2.071E-08 2.370E-04 2.752 6.100E-06 0.17 2.110E-03 
 31 9.433E-09 1.567E-03 1.254 2.309E-08 2.370E-04 3.069 5.700E-06 0.17 1.670E-03 
 33 9.242E-09 1.270E-03 1.228 2.111E-08 2.370E-04 2.806 3.300E-06 0.18 2.060E-03 
174 4 1.040E-08 1.433E-03 1.383 2.237E-08 2.370E-04 2.972 5.800E-06 0.18 1.650E-03 
 11 9.636E-09 1.319E-03 1.281 2.407E-08 2.370E-04 3.199 4.400E-06 0.20 1.410E-03 
 15 1.040E-08 1.277E-03 1.383 2.318E-08 2.370E-04 3.080 5.000E-06 0.15 2.420E-03 
 16 1.037E-08 1.158E-03 1.379 2.245E-08 2.370E-04 2.983 5.200E-06 0.19 1.990E-03 
 18 1.065E-08 1.188E-03 1.415 2.213E-08 2.370E-04 2.940 5.200E-06 0.17 1.730E-03 
 22 9.639E-09 1.113E-03 1.281 2.388E-08 2.370E-04 3.173 5.800E-06 0.15 1.810E-03 
 24 9.433E-09 1.169E-03 1.254 2.257E-08 2.370E-04 3.000 3.000E-06 0.21 2.190E-03 
 25 1.047E-08 1.179E-03 1.391 2.238E-08 2.370E-04 2.974 5.700E-06 0.16 2.530E-03 
 27 9.541E-09 1.398E-03 1.268 2.397E-08 2.370E-04 3.185 2.700E-06 0.22 2.170E-03 
 29 9.397E-09 1.234E-03 1.249 2.379E-08 2.370E-04 3.162 6.200E-06 0.16 1.610E-03 
 31 9.713E-09 1.153E-03 1.291 2.337E-08 2.370E-04 3.105 4.600E-06 0.16 1.520E-03 
 34 9.541E-09 1.359E-03 1.268 2.343E-08 2.370E-04 3.114 5.200E-06 0.17 1.570E-03 
 38 1.015E-08 1.348E-03 1.349 2.336E-08 2.370E-04 3.104 9.000E-06 0.14 2.530E-03 
 40 1.009E-08 1.438E-03 1.341 2.266E-08 2.370E-04 3.012 4.700E-06 0.15 2.740E-03 
 x� 9.867E-09 1.275E-03 1.311 
      
 x�± 3.330E-10 1.236E-04 0.044  
 
Tab.6.10: 2-component fit for calculating basal ACTH after 138 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 5 8.438E-09 1.403E-03 1.121 2.274E-08 2.130E-04 3.022 4.400E-06 0.19 1.870E-03 
 10 8.902E-09 1.290E-03 1.183 2.171E-08 2.130E-04 2.885 6.100E-06 0.18 1.520E-03 
 12 1.012E-08 1.061E-03 1.344 2.114E-08 2.130E-04 2.809 5.100E-06 0.19 1.680E-03 
 17 1.006E-08 8.733E-04 1.337 1.986E-08 2.130E-04 2.640 6.200E-06 0.16 1.160E-03 
 18 8.526E-09 1.232E-03 1.133 2.213E-08 2.130E-04 2.941 4.800E-06 0.18 1.310E-03 
 19 1.014E-08 1.159E-03 1.348 1.969E-08 2.130E-04 2.616 5.900E-06 0.17 1.320E-03 
 23 9.699E-09 1.150E-03 1.289 2.027E-08 2.130E-04 2.693 5.100E-06 0.18 1.290E-03 
 24 9.095E-09 1.158E-03 1.209 2.174E-08 2.130E-04 2.889 4.000E-06 0.18 1.930E-03 
 25 8.691E-09 1.328E-03 1.155 2.035E-08 2.130E-04 2.704 4.100E-06 0.17 1.710E-03 
 26 8.909E-09 1.009E-03 1.184 2.148E-08 2.130E-04 2.855 4.100E-06 0.17 1.330E-03 
 28 9.781E-09 1.089E-03 1.300 2.111E-08 2.130E-04 2.806 7.700E-06 0.17 2.040E-03 
 29 9.053E-09 1.206E-03 1.203 2.157E-08 2.130E-04 2.867 4.600E-06 0.19 1.180E-03 
 30 8.529E-09 1.053E-03 1.133 2.110E-08 2.130E-04 2.804 4.300E-06 0.18 1.270E-03 
 32 9.675E-09 9.789E-04 1.286 2.074E-08 2.130E-04 2.756 6.200E-06 0.17 1.300E-03 
 33 8.913E-09 1.089E-03 1.184 2.110E-08 2.130E-04 2.805 5.600E-06 0.18 1.120E-03 
 35 9.457E-09 1.117E-03 1.257 2.112E-08 2.130E-04 2.807 5.600E-06 0.17 9.930E-04 
 36 9.779E-09 9.800E-04 1.300 1.953E-08 2.130E-04 2.595 4.700E-06 0.17 1.060E-03 
 39 9.534E-09 9.739E-04 1.267 1.989E-08 2.130E-04 2.644 5.800E-06 0.17 1.690E-03 
181 1 1.065E-08 9.977E-04 1.416 2.291E-08 2.310E-04 3.044 4.300E-06 0.22 1.340E-03 
 3 8.954E-09 1.127E-03 1.190 2.118E-08 2.310E-04 2.815 3.700E-06 0.21 2.310E-03 
 7 8.567E-09 1.293E-03 1.139 2.209E-08 2.310E-04 2.935 5.100E-06 0.18 1.980E-03 
 8 9.224E-09 1.310E-03 1.226 2.070E-08 2.310E-04 2.751 7.300E-06 0.16 1.740E-03 
 9 8.922E-09 9.939E-04 1.186 2.252E-08 2.310E-04 2.993 1.000E-05 0.16 1.770E-03 
 11 8.387E-09 1.230E-03 1.115 2.195E-08 2.310E-04 2.917 7.000E-06 0.16 1.920E-03 
 12 8.318E-09 1.697E-03 1.105 2.224E-08 2.310E-04 2.955 7.500E-06 0.17 1.570E-03 
 13 1.032E-08 1.049E-03 1.372 2.061E-08 2.310E-04 2.739 1.000E-05 0.16 1.710E-03 
 18 8.973E-09 1.074E-03 1.192 2.164E-08 2.310E-04 2.876 1.000E-05 0.15 2.800E-03 
 21 9.486E-09 9.244E-04 1.261 2.134E-08 2.310E-04 2.836 6.600E-06 0.18 2.070E-03 
 26 1.006E-08 8.878E-04 1.337 2.033E-08 2.310E-04 2.701 5.300E-06 0.20 2.300E-03 
 28 8.888E-09 1.399E-03 1.181 2.078E-08 2.310E-04 2.761 6.800E-06 0.18 2.060E-03 
 30 1.041E-08 9.603E-04 1.383 2.000E-08 2.310E-04 2.657 8.200E-06 0.17 2.240E-03 
 30 1.041E-08 9.603E-04 1.383 2.000E-08 2.310E-04 2.657 8.200E-06 0.17 2.240E-03 
 32 1.008E-08 1.140E-03 1.339 2.067E-08 2.310E-04 2.747 7.600E-06 0.19 1.780E-03 
 34 1.019E-08 1.025E-03 1.355 2.024E-08 2.310E-04 2.690 7.800E-06 0.17 1.550E-03 
 35 8.398E-09 1.274E-03 1.116 2.150E-08 2.310E-04 2.858 5.700E-06 0.17 2.110E-03 
 36 9.996E-09 1.081E-03 1.328 2.059E-08 2.310E-04 2.736 5.500E-06 0.18 2.340E-03 
 38 8.163E-09 1.469E-03 1.085 2.182E-08 2.310E-04 2.900 4.800E-06 0.19 2.070E-03 
 39 9.234E-09 9.852E-04 1.227 2.125E-08 2.310E-04 2.824 5.800E-06 0.16 2.900E-03 
 41 8.224E-09 1.153E-03 1.093 2.273E-08 2.310E-04 3.021 5.700E-06 0.19 2.350E-03 
6 Appendix   
70 
 43 8.909E-09 1.168E-03 1.184 2.164E-08 2.310E-04 2.876 8.000E-06 0.17 2.400E-03 
 44 1.042E-08 8.956E-04 1.385 2.135E-08 2.310E-04 2.838 8.500E-06 0.19 1.800E-03 
 50 8.194E-09 1.100E-03 1.089 2.209E-08 2.310E-04 2.936 4.700E-06 0.18 1.250E-03 
 x� 9.302E-09 1.127E-03 1.236       
 x�± 6.444E-10 1.318E-04 0.086  
 
Tab.6.11: 2-component fit for calculating ACTH response to 10nM CRH (1 min) after 92 h 
  
Fig. 6.7: Concdiff-plot of 2-component fit to 10nM CRH (1 min) after 92 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 8.977E-09 9.973E-04 1.193 2.045E-08 2.130E-04 2.718 4.300E-06 0.16 2.440E-03 
 2 1.025E-08 1.136E-03 1.362 2.015E-08 2.130E-04 2.678 1.000E-05 0.15 1.830E-03 
 3 9.532E-09 1.070E-03 1.267 2.020E-08 2.130E-04 2.684 7.000E-06 0.18 1.510E-03 
 4 9.099E-09 1.159E-03 1.209 1.894E-08 2.130E-04 2.517 5.900E-06 0.17 1.910E-03 
 5 9.798E-09 1.029E-03 1.302 1.871E-08 2.130E-04 2.486 7.100E-06 0.16 2.840E-03 
 8 1.028E-08 8.581E-04 1.366 1.785E-08 2.130E-04 2.372 5.000E-06 0.19 2.370E-03 
 10 9.113E-09 1.087E-03 1.211 1.976E-08 2.130E-04 2.626 4.500E-06 0.18 2.670E-03 
 17 9.793E-09 9.606E-04 1.301 1.830E-08 2.130E-04 2.432 6.700E-06 0.18 1.590E-03 
 18 8.898E-09 1.323E-03 1.183 1.916E-08 2.130E-04 2.547 6.100E-06 0.16 1.670E-03 
 19 9.618E-09 1.076E-03 1.278 1.837E-08 2.130E-04 2.441 6.700E-06 0.16 1.660E-03 
 22 8.943E-09 1.089E-03 1.188 1.830E-08 2.130E-04 2.431 4.600E-06 0.19 3.040E-03 
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 24 9.381E-09 1.122E-03 1.247 1.881E-08 2.130E-04 2.500 7.000E-06 0.16 2.430E-03 
 25 9.829E-09 9.859E-04 1.306 1.780E-08 2.130E-04 2.366 7.300E-06 0.16 2.150E-03 
 26 1.005E-08 8.852E-04 1.335 1.775E-08 2.130E-04 2.359 3.600E-06 0.22 2.430E-03 
 27 9.453E-09 1.059E-03 1.256 1.807E-08 2.130E-04 2.402 6.300E-06 0.17 1.690E-03 
 31 9.284E-09 1.142E-03 1.234 1.903E-08 2.130E-04 2.529 4.700E-06 0.18 1.780E-03 
 34 9.704E-09 8.702E-04 1.290 1.913E-08 2.130E-04 2.542 6.400E-06 0.17 2.540E-03 
 36 9.057E-09 1.114E-03 1.204 1.860E-08 2.130E-04 2.472 6.900E-06 0.16 1.360E-03 
 40 9.199E-09 1.054E-03 1.222 1.819E-08 2.130E-04 2.417 4.600E-06 0.20 1.720E-03 
183 2 9.796E-09 1.251E-03 1.302 2.081E-08 2.310E-04 2.765 7.500E-06 0.16 2.090E-03 
 9 1.000E-08 9.021E-04 1.329 1.919E-08 2.310E-04 2.550 6.100E-06 0.15 1.900E-03 
 10 1.045E-08 1.021E-03 1.388 1.981E-08 2.310E-04 2.633 7.600E-06 0.18 2.350E-03 
 12 9.455E-09 1.318E-03 1.256 2.034E-08 2.310E-04 2.702 5.700E-06 0.18 1.640E-03 
 14 8.729E-09 1.347E-03 1.160 2.045E-08 2.310E-04 2.717 5.300E-06 0.18 2.430E-03 
 15 9.542E-09 1.183E-03 1.268 2.075E-08 2.310E-04 2.758 8.600E-06 0.15 2.460E-03 
 16 9.796E-09 1.251E-03 1.302 2.081E-08 2.310E-04 2.765 7.500E-06 0.16 2.090E-03 
 17 9.849E-09 1.130E-03 1.309 2.081E-08 2.310E-04 2.766 9.900E-06 0.15 2.020E-03 
 18 9.133E-09 1.144E-03 1.214 2.172E-08 2.310E-04 2.887 5.300E-06 0.18 2.950E-03 
 19 9.714E-09 8.529E-04 1.291 2.149E-08 2.310E-04 2.856 6.100E-06 0.17 2.170E-03 
 20 1.036E-08 9.696E-04 1.377 1.905E-08 2.310E-04 2.532 6.400E-06 0.17 1.680E-03 
 21 9.708E-09 9.834E-04 1.290 2.054E-08 2.310E-04 2.729 3.300E-06 0.21 1.660E-03 
 23 1.022E-08 1.104E-03 1.358 2.030E-08 2.310E-04 2.698 9.500E-06 0.16 1.930E-03 
 25 8.417E-09 1.196E-03 1.119 2.207E-08 2.310E-04 2.933 5.300E-06 0.19 1.540E-03 
 26 8.623E-09 9.882E-04 1.146 2.093E-08 2.310E-04 2.781 4.000E-06 0.20 2.140E-03 
 27 1.002E-08 1.148E-03 1.332 2.163E-08 2.310E-04 2.875 1.000E-05 0.16 1.760E-03 
 32 9.669E-09 1.017E-03 1.285 2.131E-08 2.310E-04 2.832 8.900E-06 0.16 1.470E-03 
 34 9.175E-09 1.036E-03 1.219 2.078E-08 2.310E-04 2.761 5.500E-06 0.19 1.620E-03 
 37 8.895E-09 1.027E-03 1.182 2.101E-08 2.310E-04 2.791 4.600E-06 0.18 2.330E-03 
 39 9.896E-09 1.179E-03 1.315 2.036E-08 2.310E-04 2.706 6.700E-06 0.17 2.250E-03 
 40 1.018E-08 1.050E-03 1.352 2.076E-08 2.310E-04 2.759 6.200E-06 0.18 2.090E-03 
 43 9.348E-09 1.064E-03 1.242 2.155E-08 2.310E-04 2.863 6.500E-06 0.18 1.640E-03 
 46 8.463E-09 1.187E-03 1.125 2.171E-08 2.310E-04 2.885 4.600E-06 0.20 2.060E-03 
 48 9.651E-09 8.375E-04 1.283 2.137E-08 2.310E-04 2.840 4.900E-06 0.19 2.400E-03 
 x� 9.514E-09 1.074E-03 1.264 
      
 x�± 4.258E-10 9.691E-05 0.057  
 
Tab.6.12: 2-component fit for calculating ACTH response to 10nM CRH (15 min) after 92 h 
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Fig. 6.8: Concdiff-plot of 2-component fit to 10nM CRH (15 min) after 92 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 9.826E-09 8.873E-04 1.306 2.039E-08 2.310E-04 2.709 4.700E-06 0.18 1.200E-03 
 2 1.102E-08 8.746E-04 1.464 2.011E-08 2.310E-04 2.672 6.100E-06 0.20 2.040E-03 
 3 1.067E-08 8.900E-04 1.418 1.927E-08 2.310E-04 2.561 7.200E-06 0.17 1.830E-03 
 6 8.585E-09 1.023E-03 1.141 1.984E-08 2.310E-04 2.636 6.600E-06 0.18 1.910E-03 
 7 9.249E-09 9.803E-04 1.229 1.998E-08 2.310E-04 2.655 8.700E-06 0.17 1.800E-03 
 10 9.908E-09 8.000E-04 1.317 2.040E-08 2.310E-04 2.711 6.400E-06 0.20 1.760E-03 
 11 9.496E-09 8.493E-04 1.262 1.960E-08 2.310E-04 2.605 5.300E-06 0.21 2.350E-03 
 14 9.809E-09 9.729E-04 1.304 1.717E-08 2.310E-04 2.282 6.500E-06 0.17 1.340E-03 
 15 9.898E-09 9.604E-04 1.315 1.892E-08 2.310E-04 2.515 9.900E-06 0.17 1.340E-03 
 16 9.557E-09 9.226E-04 1.270 1.880E-08 2.310E-04 2.498 6.600E-06 0.17 1.970E-03 
 20 9.074E-09 1.042E-03 1.206 1.913E-08 2.310E-04 2.543 7.500E-06 0.17 2.370E-03 
 26 1.015E-08 8.759E-04 1.348 1.911E-08 2.310E-04 2.540 4.900E-06 0.20 2.250E-03 
 27 1.121E-08 8.156E-04 1.490 1.681E-08 2.310E-04 2.234 7.900E-06 0.17 2.230E-03 
 29 8.924E-09 8.526E-04 1.186 1.884E-08 2.310E-04 2.504 5.200E-06 0.18 1.530E-03 
 30 1.007E-08 8.239E-04 1.339 1.858E-08 2.310E-04 2.469 5.400E-06 0.19 1.440E-03 
 31 8.928E-09 9.834E-04 1.186 1.983E-08 2.310E-04 2.635 6.400E-06 0.17 2.180E-03 
 33 1.104E-08 8.931E-04 1.467 1.768E-08 2.310E-04 2.350 6.500E-06 0.19 1.400E-03 
 39 8.588E-09 1.059E-03 1.141 2.014E-08 2.310E-04 2.676 6.800E-06 0.18 1.510E-03 
 43 1.017E-08 9.057E-04 1.352 1.861E-08 2.310E-04 2.473 8.400E-06 0.18 1.790E-03 
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 50 8.768E-09 1.078E-03 1.165 1.908E-08 2.310E-04 2.536 5.900E-06 0.17 1.690E-03 
 x� 9.706E-09 9.340E-04 1.290 
      
 x�± 6.669E-10 7.783E-05 0.088 
 
 
Tab.6.13: 2-component fit for calculating ACTH response to 10nM CRH (30 min) after 92 h 
  
Fig. 6.9: Concdiff-plot of 2-component fit to 10nM CRH (30 min) after 92 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 3 1.027E-08 1.147E-03 1.365 2.102E-08 2.130E-04 2.793 4.200E-06 0.18 2.450E-03 
 4 9.046E-09 1.269E-03 1.202 2.242E-08 2.130E-04 2.979 4.500E-06 0.18 2.490E-03 
 5 9.812E-09 1.211E-03 1.304 1.930E-08 2.130E-04 2.565 7.400E-06 0.16 2.190E-03 
 6 9.807E-09 1.051E-03 1.303 1.977E-08 2.130E-04 2.627 5.500E-06 0.15 2.360E-03 
 8 9.020E-09 1.166E-03 1.199 1.974E-08 2.130E-04 2.623 5.800E-06 0.17 1.840E-03 
 9 1.031E-08 1.045E-03 1.370 1.832E-08 2.130E-04 2.435 5.500E-06 0.17 1.830E-03 
 10 9.246E-09 1.158E-03 1.229 2.078E-08 2.130E-04 2.761 8.400E-06 0.14 2.010E-03 
 11 1.030E-08 1.067E-03 1.368 1.951E-08 2.130E-04 2.592 7.700E-06 0.13 1.990E-03 
 12 9.818E-09 1.040E-03 1.305 1.973E-08 2.130E-04 2.622 4.800E-06 0.19 2.870E-03 
 13 9.341E-09 1.109E-03 1.241 2.030E-08 2.130E-04 2.697 6.800E-06 0.16 2.990E-03 
 14 1.048E-08 1.019E-03 1.393 1.897E-08 2.130E-04 2.521 6.400E-06 0.16 2.980E-03 
 15 1.032E-08 1.043E-03 1.371 2.025E-08 2.130E-04 2.691 6.100E-06 0.20 1.650E-03 
 17 9.339E-09 1.124E-03 1.241 2.114E-08 2.130E-04 2.809 5.500E-06 0.17 1.140E-03 
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 20 9.966E-09 1.015E-03 1.324 1.982E-08 2.130E-04 2.634 5.600E-06 0.18 2.150E-03 
 21 8.972E-09 1.158E-03 1.192 1.977E-08 2.130E-04 2.628 6.000E-06 0.17 2.780E-03 
 22 9.958E-09 1.074E-03 1.323 1.859E-08 2.130E-04 2.471 5.500E-06 0.16 2.740E-03 
 24 1.005E-08 8.858E-04 1.335 2.071E-08 2.130E-04 2.752 6.700E-06 0.18 2.710E-03 
 26 1.015E-08 1.021E-03 1.349 1.926E-08 2.130E-04 2.559 5.100E-06 0.18 2.470E-03 
 29 9.189E-09 8.799E-04 1.221 2.109E-08 2.130E-04 2.802 5.500E-06 0.19 3.010E-03 
 31 9.783E-09 1.118E-03 1.300 1.971E-08 2.130E-04 2.620 5.700E-06 0.16 2.620E-03 
 32 9.642E-09 1.176E-03 1.281 1.995E-08 2.130E-04 2.651 6.200E-06 0.16 1.970E-03 
 35 1.006E-08 8.278E-04 1.337 1.876E-08 2.130E-04 2.493 5.600E-06 0.16 3.690E-03 
 36 9.465E-09 1.083E-03 1.258 2.154E-08 2.130E-04 2.862 7.700E-06 0.19 1.670E-03 
 37 9.485E-09 9.462E-04 1.261 2.072E-08 2.130E-04 2.753 6.700E-06 0.18 3.660E-03 
 40 8.998E-09 1.214E-03 1.196 1.982E-08 2.130E-04 2.634 5.000E-06 0.16 1.120E-03 
 42 9.750E-09 9.773E-04 1.296 1.986E-08 2.130E-04 2.640 6.000E-06 0.15 2.740E-03 
 43 9.543E-09 9.778E-04 1.268 1.999E-08 2.130E-04 2.656 6.200E-06 0.15 2.280E-03 
 44 9.660E-09 1.194E-03 1.284 2.038E-08 2.130E-04 2.709 6.200E-06 0.15 2.380E-03 
 45 1.002E-08 9.604E-04 1.331 1.941E-08 2.130E-04 2.579 5.800E-06 0.19 3.630E-03 
 46 1.042E-08 8.568E-04 1.384 1.901E-08 2.130E-04 2.526 5.600E-06 0.16 1.760E-03 
 47 1.008E-08 9.760E-04 1.339 1.971E-08 2.130E-04 2.619 5.800E-06 0.16 2.230E-03 
 50 9.567E-09 9.428E-04 1.271 1.943E-08 2.130E-04 2.582 4.100E-06 0.17 2.790E-03 
 x� 9.771E-09 1.053E-03 1.298 
      
 x�± 3.823E-10 8.900E-05 0.051  
 
Tab.6.14: 2-component fit for calculating ACTH response to 10nM CRH (1 h) after 92 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 1.151E-08 1.094E-03 1.530 2.252E-08 2.310E-04 2.992 8.500E-06 0.17 1.010E-03 
 2 1.014E-08 1.338E-03 1.348 2.253E-08 2.310E-04 2.995 6.300E-06 0.19 1.270E-03 
 4 1.010E-08 9.464E-04 1.342 2.267E-08 2.310E-04 3.013 7.900E-06 0.17 1.600E-03 
 5 1.011E-08 1.101E-03 1.343 2.265E-08 2.310E-04 3.010 8.600E-06 0.17 1.530E-03 
 8 9.242E-09 1.401E-03 1.228 2.256E-08 2.310E-04 2.998 5.700E-06 0.19 2.110E-03 
 12 1.024E-08 9.997E-04 1.361 2.026E-08 2.310E-04 2.692 6.500E-06 0.17 1.230E-03 
 15 9.491E-09 1.212E-03 1.261 2.281E-08 2.310E-04 3.032 6.800E-06 0.17 2.200E-03 
 16 9.240E-09 1.225E-03 1.228 2.009E-08 2.310E-04 2.670 5.000E-06 0.17 1.790E-03 
 21 1.141E-08 1.028E-03 1.516 2.036E-08 2.310E-04 2.706 7.700E-06 0.20 1.570E-03 
 22 9.908E-09 1.147E-03 1.317 2.150E-08 2.310E-04 2.857 8.200E-06 0.15 2.670E-03 
 24 1.116E-08 1.029E-03 1.483 2.028E-08 2.310E-04 2.695 8.100E-06 0.18 1.380E-03 
 25 1.096E-08 1.064E-03 1.456 2.140E-08 2.310E-04 2.844 8.400E-06 0.17 1.820E-03 
 26 9.140E-09 1.292E-03 1.215 2.217E-08 2.310E-04 2.946 5.400E-06 0.17 1.700E-03 
 28 9.255E-09 1.270E-03 1.230 2.210E-08 2.310E-04 2.937 9.300E-06 0.14 1.330E-03 
 31 1.155E-08 9.454E-04 1.536 1.924E-08 2.310E-04 2.557 7.400E-06 0.18 2.380E-03 
 37 9.403E-09 1.030E-03 1.250 2.204E-08 2.310E-04 2.929 6.900E-06 0.17 2.290E-03 
 38 9.733E-09 1.091E-03 1.293 2.194E-08 2.310E-04 2.916 6.100E-06 0.18 1.510E-03 
 39 1.026E-08 1.092E-03 1.364 1.901E-08 2.310E-04 2.527 5.200E-06 0.16 2.170E-03 
 x� 1.016E-08 1.128E-03 1.350 
      
 x�± 6.645E-10 1.098E-04 0.088  
 
Tab.6.15: 2-component fit for calculating ACTH response to 10nM CRH (2 h) after 92 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 2 9.390E-09 1.060E-03 1.250 1.930E-08 2.140E-04 2.570 4.500E-06 0.19 2.210E-03 
 10 9.710E-09 1.030E-03 1.290 1.910E-08 2.140E-04 2.530 9.100E-06 0.16 1.950E-03 
 13 9.130E-09 1.160E-03 1.210 2.000E-08 2.140E-04 2.660 6.300E-06 0.19 1.920E-03 
 14 9.670E-09 1.060E-03 1.280 1.950E-08 2.140E-04 2.600 6.600E-06 0.19 2.410E-03 
 15 9.060E-09 1.100E-03 1.200 1.980E-08 2.140E-04 2.630 8.200E-06 0.18 2.280E-03 
 17 1.010E-08 9.890E-04 1.340 1.980E-08 2.140E-04 2.630 5.800E-06 0.19 2.820E-03 
 18 9.980E-09 1.030E-03 1.330 1.880E-08 2.140E-04 2.500 5.500E-06 0.19 2.150E-03 
 23 9.320E-09 1.080E-03 1.240 1.970E-08 2.140E-04 2.620 5.200E-06 0.20 2.550E-03 
 25 9.730E-09 9.560E-04 1.290 1.880E-08 2.140E-04 2.500 6.200E-06 0.18 3.040E-03 
 27 9.120E-09 1.090E-03 1.210 2.020E-08 2.140E-04 2.680 5.600E-06 0.20 2.930E-03 
 38 9.460E-09 1.080E-03 1.260 2.020E-08 2.140E-04 2.680 6.400E-06 0.18 2.670E-03 
 40 9.820E-09 1.050E-03 1.310 2.000E-08 2.140E-04 2.660 8.000E-06 0.18 3.680E-03 
 x� 9.541E-09 1.057E-03 1.268 
      
 x�± 2.942E-10 3.840E-05 0.039  
 
Tab.6.16: 2-component fit for calculating ACTH response to 10nM CRH (1 min) after 114 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 2 8.543E-09 1.520E-03 1.135 2.405E-08 2.140E-04 3.196 3.800E-06 0.18 1.840E-03 
 4 1.158E-08 9.644E-04 1.538 2.082E-08 2.140E-04 2.766 4.400E-06 0.20 2.400E-03 
 5 1.105E-08 1.086E-03 1.468 2.083E-08 2.140E-04 2.769 4.100E-06 0.21 1.350E-03 
 7 1.058E-08 9.657E-04 1.406 2.159E-08 2.140E-04 2.870 3.800E-06 0.23 2.150E-03 
 8 8.321E-09 1.394E-03 1.106 2.285E-08 2.140E-04 3.037 4.500E-06 0.18 1.830E-03 
 9 9.615E-09 1.245E-03 1.278 2.230E-08 2.140E-04 2.964 4.500E-06 0.20 2.810E-03 
 11 9.166E-09 1.227E-03 1.218 2.300E-08 2.140E-04 3.056 3.300E-06 0.21 3.200E-03 
 12 8.469E-09 1.658E-03 1.125 2.281E-08 2.140E-04 3.032 6.000E-06 0.16 2.320E-03 
 14 9.659E-09 1.264E-03 1.284 2.165E-08 2.140E-04 2.876 5.800E-06 0.18 1.420E-03 
 15 1.026E-08 1.103E-03 1.364 2.234E-08 2.140E-04 2.969 5.400E-06 0.19 1.280E-03 
 16 8.769E-09 1.309E-03 1.165 2.286E-08 2.140E-04 3.037 4.200E-06 0.19 1.890E-03 
 17 1.118E-08 1.071E-03 1.486 2.100E-08 2.140E-04 2.791 5.500E-06 0.20 2.100E-03 
 20 9.472E-09 1.275E-03 1.259 2.318E-08 2.140E-04 3.080 6.100E-06 0.18 1.270E-03 
 22 1.069E-08 1.074E-03 1.421 2.117E-08 2.140E-04 2.813 6.600E-06 0.19 1.420E-03 
 23 8.554E-09 1.340E-03 1.137 2.258E-08 2.140E-04 3.000 4.900E-06 0.18 1.830E-03 
 24 1.155E-08 1.078E-03 1.535 2.107E-08 2.140E-04 2.799 7.800E-06 0.18 1.060E-03 
 25 9.679E-09 1.213E-03 1.286 2.268E-08 2.140E-04 3.014 4.900E-06 0.21 1.420E-03 
 26 1.092E-08 9.245E-04 1.452 2.115E-08 2.140E-04 2.810 5.600E-06 0.19 1.470E-03 
 28 8.582E-09 1.365E-03 1.141 2.405E-08 2.140E-04 3.196 3.700E-06 0.18 1.830E-03 
 29 9.328E-09 1.270E-03 1.240 2.349E-08 2.140E-04 3.121 3.700E-06 0.23 1.210E-03 
 30 1.093E-08 1.129E-03 1.453 2.169E-08 2.140E-04 2.882 7.000E-06 0.18 1.510E-03 
 31 9.681E-09 1.000E-03 1.286 2.325E-08 2.140E-04 3.090 5.000E-06 0.18 1.640E-03 
 32 1.089E-08 8.712E-04 1.447 2.083E-08 2.140E-04 2.769 6.000E-06 0.17 1.760E-03 
 34 1.090E-08 1.026E-03 1.448 2.095E-08 2.140E-04 2.784 6.000E-06 0.17 2.570E-03 
 35 8.889E-09 1.505E-03 1.181 2.270E-08 2.140E-04 3.016 5.900E-06 0.15 1.980E-03 
 36 8.924E-09 1.170E-03 1.186 2.295E-08 2.140E-04 3.050 3.100E-06 0.25 1.720E-03 
 37 1.062E-08 8.000E-04 1.411 2.205E-08 2.140E-04 2.930 5.900E-06 0.20 1.710E-03 
 38 9.950E-09 1.241E-03 1.322 2.289E-08 2.140E-04 3.041 4.400E-06 0.22 1.840E-03 
 39 8.245E-09 1.343E-03 1.096 2.377E-08 2.140E-04 3.159 2.600E-06 0.21 1.500E-03 
 x� 9.827E-09 1.187E-03 1.306 
      
 x�± 9.202E-10 1.627E-04 0.122 
 
 
Tab.6.17: 2-component fit for calculating ACTH response to 10nM CRH (15 min) after 114 h 
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Fig. 6.13: Concdiff-plot of 2-component fit to 10nM CRH (15 min) after 114 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 9.905E-09 9.943E-04 1.316 2.262E-08 2.140E-04 3.005 3.100E-06 0.19 2.150E-03 
 5 1.042E-08 1.278E-03 1.385 2.162E-08 2.140E-04 2.873 5.900E-06 0.17 1.530E-03 
 11 9.420E-09 1.210E-03 1.252 2.278E-08 2.140E-04 3.027 3.700E-06 0.19 1.620E-03 
 14 1.008E-08 9.713E-04 1.340 2.240E-08 2.140E-04 2.977 1.000E-05 0.15 1.250E-03 
 25 9.831E-09 1.211E-03 1.306 2.138E-08 2.140E-04 2.842 4.300E-06 0.18 2.530E-03 
 27 1.009E-08 1.077E-03 1.341 2.163E-08 2.140E-04 2.874 5.300E-06 0.16 2.550E-03 
 31 9.290E-09 1.315E-03 1.235 2.115E-08 2.140E-04 2.811 4.100E-06 0.17 2.340E-03 
 33 9.158E-09 1.213E-03 1.217 2.239E-08 2.140E-04 2.976 4.300E-06 0.15 1.570E-03 
 35 9.953E-09 1.318E-03 1.323 2.015E-08 2.140E-04 2.678 4.600E-06 0.16 1.730E-03 
 37 1.051E-08 1.029E-03 1.396 1.977E-08 2.140E-04 2.627 2.700E-06 0.21 1.890E-03 
 x� 9.866E-09 1.162E-03 1.311 
      
 x�± 3.528E-10 1.150E-04 0.047 
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Fig. 6.14: Concdiff-plot of 2-component fit to 10nM CRH (30 min) after 114 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 1.035E-08 1.040E-03 1.376 2.329E-08 2.140E-04 3.095 5.500E-06 0.16 1.530E-03 
 2 9.027E-09 1.588E-03 1.200 2.525E-08 2.140E-04 3.355 9.900E-06 0.18 1.410E-03 
 4 1.006E-08 1.376E-03 1.337 2.208E-08 2.140E-04 2.934 3.700E-06 0.21 1.630E-03 
 5 8.753E-09 1.616E-03 1.163 2.403E-08 2.140E-04 3.194 4.100E-06 0.18 1.340E-03 
 7 1.086E-08 1.243E-03 1.443 2.282E-08 2.140E-04 3.032 6.000E-06 0.17 1.510E-03 
 8 9.680E-09 1.433E-03 1.286 2.442E-08 2.140E-04 3.245 7.200E-06 0.17 1.410E-03 
 9 9.114E-09 1.595E-03 1.211 2.236E-08 2.140E-04 2.972 4.400E-06 0.19 1.820E-03 
 10 1.095E-08 1.339E-03 1.456 2.388E-08 2.140E-04 3.173 8.100E-06 0.18 1.730E-03 
 12 1.039E-08 1.113E-03 1.381 2.281E-08 2.140E-04 3.031 6.600E-06 0.16 1.440E-03 
 13 1.094E-08 1.211E-03 1.454 2.159E-08 2.140E-04 2.870 4.500E-06 0.20 2.640E-03 
 14 1.035E-08 1.437E-03 1.375 2.238E-08 2.140E-04 2.975 6.000E-06 0.17 9.020E-04 
 16 1.017E-08 1.128E-03 1.352 2.161E-08 2.140E-04 2.872 5.500E-06 0.17 1.510E-03 
 17 9.015E-09 1.314E-03 1.198 2.259E-08 2.140E-04 3.003 4.100E-06 0.19 1.610E-03 
 18 1.040E-08 1.059E-03 1.383 2.208E-08 2.140E-04 2.934 4.800E-06 0.19 1.420E-03 
 19 1.088E-08 1.036E-03 1.446 2.202E-08 2.140E-04 2.927 6.800E-06 0.18 1.560E-03 
 20 9.720E-09 1.393E-03 1.292 2.138E-08 2.140E-04 2.842 4.200E-06 0.20 1.250E-03 
 22 9.690E-09 1.116E-03 1.288 2.233E-08 2.140E-04 2.967 6.600E-06 0.17 1.360E-03 
 24 1.124E-08 1.164E-03 1.494 2.013E-08 2.140E-04 2.675 6.400E-06 0.18 2.170E-03 
 27 1.035E-08 1.152E-03 1.375 2.208E-08 2.140E-04 2.934 5.600E-06 0.17 1.810E-03 
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 29 9.983E-09 1.176E-03 1.327 2.227E-08 2.140E-04 2.959 7.700E-06 0.15 1.230E-03 
 30 9.301E-09 1.105E-03 1.236 2.270E-08 2.140E-04 3.016 6.700E-06 0.15 1.340E-03 
 31 9.716E-09 1.088E-03 1.291 2.227E-08 2.140E-04 2.960 4.500E-06 0.15 2.750E-03 
 33 1.018E-08 1.074E-03 1.353 2.293E-08 2.140E-04 3.047 5.500E-06 0.20 1.520E-03 
 34 9.994E-09 1.015E-03 1.328 2.357E-08 2.140E-04 3.132 5.100E-06 0.19 1.390E-03 
 35 9.620E-09 1.415E-03 1.278 2.405E-08 2.140E-04 3.196 5.700E-06 0.18 1.540E-03 
 36 1.021E-08 1.398E-03 1.357 2.201E-08 2.140E-04 2.924 5.400E-06 0.18 1.010E-03 
 37 1.062E-08 1.137E-03 1.412 2.266E-08 2.140E-04 3.012 4.900E-06 0.20 1.830E-03 
 39 8.617E-09 1.299E-03 1.145 2.388E-08 2.140E-04 3.174 3.800E-06 0.19 1.630E-03 
194 2 9.084E-09 1.070E-03 1.207 1.792E-08 2.140E-04 2.382 3.100E-06 0.19 2.250E-03 
 4 1.091E-08 9.445E-04 1.449 1.605E-08 2.140E-04 2.133 6.100E-06 0.18 1.890E-03 
 5 9.581E-09 8.786E-04 1.273 1.744E-08 2.140E-04 2.317 7.900E-06 0.14 1.760E-03 
 7 9.768E-09 1.074E-03 1.298 1.660E-08 2.140E-04 2.206 5.200E-06 0.16 1.700E-03 
 8 8.936E-09 1.065E-03 1.187 1.818E-08 2.140E-04 2.416 4.000E-06 0.20 2.550E-03 
 10 9.214E-09 1.232E-03 1.225 1.662E-08 2.140E-04 2.209 6.100E-06 0.15 2.890E-03 
 11 9.983E-09 9.781E-04 1.327 1.712E-08 2.140E-04 2.275 7.600E-06 0.13 2.230E-03 
 14 1.045E-08 8.926E-04 1.389 1.570E-08 2.140E-04 2.086 5.400E-06 0.16 2.610E-03 
 15 1.001E-08 9.687E-04 1.330 1.546E-08 2.140E-04 2.054 5.800E-06 0.14 2.430E-03 
 16 1.049E-08 1.015E-03 1.394 1.753E-08 2.140E-04 2.330 6.800E-06 0.17 1.300E-03 
 20 8.990E-09 1.040E-03 1.195 1.759E-08 2.140E-04 2.337 3.200E-06 0.19 1.840E-03 
 23 8.973E-09 1.128E-03 1.192 1.778E-08 2.140E-04 2.363 2.500E-06 0.20 2.410E-03 
 24 1.119E-08 8.803E-04 1.487 1.544E-08 2.140E-04 2.052 4.400E-06 0.17 3.030E-03 
 26 1.028E-08 9.810E-04 1.366 1.642E-08 2.140E-04 2.182 3.300E-06 0.18 2.130E-03 
 27 1.007E-08 1.047E-03 1.339 1.726E-08 2.140E-04 2.294 4.300E-06 0.18 1.680E-03 
 29 9.370E-09 1.006E-03 1.245 1.791E-08 2.140E-04 2.380 4.100E-06 0.17 2.350E-03 
 30 1.127E-08 8.478E-04 1.497 1.581E-08 2.140E-04 2.101 6.000E-06 0.17 2.410E-03 
 31 9.954E-09 1.103E-03 1.323 1.721E-08 2.140E-04 2.287 5.100E-06 0.15 2.400E-03 
 32 1.012E-08 1.189E-03 1.344 1.688E-08 2.140E-04 2.243 4.900E-06 0.18 2.140E-03 
 33 1.055E-08 8.307E-04 1.403 1.607E-08 2.140E-04 2.135 9.800E-06 0.15 1.770E-03 
 38 9.597E-09 1.020E-03 1.275 1.763E-08 2.140E-04 2.343 4.800E-06 0.19 2.610E-03 
 39 1.040E-08 9.850E-04 1.382 1.585E-08 2.140E-04 2.106 7.500E-06 0.13 3.740E-03 
 x� 9.983E-09 1.145E-03 1.327 
      
 x� ± 5.546E-10 1.500E-04 0.074       
Tab.6.19: 2-component fit for calculating ACTH response to 10nM CRH (1 h) after 114 h 
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Fig. 6.15: Concdiff-plot of 2-component fit to 10nM CRH (1 h) after 114 h 
 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 2 1.046E-08 1.148E-03 1.391 2.099E-08 2.140E-04 2.789 4.100E-06 0.21 2.070E-03 
 3 1.005E-08 1.195E-03 1.336 2.002E-08 2.140E-04 2.660 5.200E-06 0.2 1.590E-03 
 4 1.064E-08 8.904E-04 1.413 1.863E-08 2.140E-04 2.476 4.300E-06 0.19 1.940E-03 
 7 1.208E-08 8.577E-04 1.606 1.777E-08 2.140E-04 2.361 9.200E-06 0.16 1.930E-03 
 8 1.080E-08 1.053E-03 1.436 1.911E-08 2.140E-04 2.540 1.000E-05 0.15 2.010E-03 
 11 1.157E-08 8.220E-04 1.537 1.869E-08 2.140E-04 2.483 9.700E-06 0.16 2.170E-03 
 12 1.154E-08 1.011E-03 1.533 1.876E-08 2.140E-04 2.493 7.200E-06 0.19 2.210E-03 
 13 1.034E-08 1.129E-03 1.374 1.930E-08 2.140E-04 2.564 5.600E-06 0.17 1.820E-03 
 15 1.186E-08 9.359E-04 1.576 1.746E-08 2.140E-04 2.321 7.800E-06 0.15 2.210E-03 
 18 1.006E-08 9.147E-04 1.337 1.950E-08 2.140E-04 2.591 5.800E-06 0.18 2.120E-03 
 24 1.050E-08 9.755E-04 1.396 1.988E-08 2.140E-04 2.642 4.800E-06 0.2 2.720E-03 
 26 1.110E-08 8.901E-04 1.475 1.806E-08 2.140E-04 2.400 7.000E-06 0.18 2.320E-03 
 27 9.768E-09 1.012E-03 1.298 2.017E-08 2.140E-04 2.680 4.900E-06 0.18 2.330E-03 
 28 1.205E-08 1.045E-03 1.601 1.845E-08 2.140E-04 2.451 7.600E-06 0.19 2.330E-03 
 30 9.684E-09 1.044E-03 1.287 2.027E-08 2.140E-04 2.694 5.100E-06 0.2 1.720E-03 
 31 1.251E-08 8.370E-04 1.662 1.719E-08 2.140E-04 2.284 7.000E-06 0.17 2.960E-03 
 32 1.020E-08 1.113E-03 1.356 1.870E-08 2.140E-04 2.484 3.800E-06 0.2 2.440E-03 
 36 9.662E-09 1.293E-03 1.284 1.978E-08 2.140E-04 2.628 5.900E-06 0.18 1.480E-03 
 37 1.142E-08 9.395E-04 1.518 1.843E-08 2.140E-04 2.450 9.000E-06 0.16 2.240E-03 
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 40 1.051E-08 9.146E-04 1.396 1.905E-08 2.140E-04 2.531 5.400E-06 0.19 2.000E-03 
195 2 1.152E-08 8.491E-04 1.530 1.547E-08 2.140E-04 2.056 4.400E-06 0.17 2.490E-03 
 3 1.101E-08 8.000E-04 1.463 1.443E-08 2.140E-04 1.918 7.300E-06 0.1 2.380E-03 
 5 9.632E-09 8.000E-04 1.280 1.532E-08 2.140E-04 2.036 6.300E-06 0.12 2.390E-03 
 6 9.618E-09 8.000E-04 1.278 1.429E-08 2.140E-04 1.899 3.500E-06 0.15 2.720E-03 
 7 1.131E-08 8.187E-04 1.503 1.395E-08 2.140E-04 1.854 6.700E-06 0.15 3.120E-03 
 8 1.011E-08 8.000E-04 1.344 1.491E-08 2.140E-04 1.982 4.600E-06 0.14 2.000E-03 
 11 1.156E-08 8.000E-04 1.536 1.349E-08 2.140E-04 1.793 4.300E-06 0.17 3.780E-03 
 12 1.008E-08 8.000E-04 1.340 1.496E-08 2.140E-04 1.987 4.800E-06 0.16 3.260E-03 
 19 1.067E-08 9.056E-04 1.418 1.488E-08 2.140E-04 1.978 5.300E-06 0.17 2.670E-03 
 21 1.076E-08 8.485E-04 1.431 1.398E-08 2.140E-04 1.857 5.000E-06 0.15 2.530E-03 
 22 9.975E-09 9.528E-04 1.326 1.495E-08 2.140E-04 1.987 5.300E-06 0.16 2.530E-03 
 25 1.021E-08 8.000E-04 1.357 1.611E-08 2.140E-04 2.141 4.400E-06 0.18 2.220E-03 
 30 1.100E-08 8.000E-04 1.461 1.413E-08 2.140E-04 1.878 4.000E-06 0.19 3.280E-03 
 32 1.008E-08 9.325E-04 1.340 1.525E-08 2.140E-04 2.026 5.500E-06 0.15 3.120E-03 
 35 1.146E-08 8.071E-04 1.524 1.419E-08 2.140E-04 1.886 6.400E-06 0.15 2.560E-03 
 39 1.056E-08 8.784E-04 1.403 1.487E-08 2.140E-04 1.976 7.000E-06 0.14 2.180E-03 
 x� 1.079E-08 9.257E-04 1.433       
 x�± 6.983E-10 1.024E-04 0.092   
Tab.6.20: 2-component fit for calculating ACTH response to 10nM CRH (2 h) after 114 h 
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 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 3 1.102E-08 9.367E-04 1.464 2.204E-08 2.370E-04 2.930 6.200E-06 0.16 1.930E-03 
 9 1.053E-08 1.109E-03 1.399 2.184E-08 2.370E-04 2.902 6.100E-06 0.18 2.230E-03 
 11 1.131E-08 1.164E-03 1.503 2.035E-08 2.370E-04 2.704 8.600E-06 0.15 2.570E-03 
 19 1.206E-08 9.679E-04 1.603 1.876E-08 2.370E-04 2.493 7.100E-06 0.14 2.030E-03 
 27 1.115E-08 1.018E-03 1.482 2.162E-08 2.370E-04 2.874 5.300E-06 0.15 2.360E-03 
 28 1.047E-08 1.138E-03 1.392 2.247E-08 2.370E-04 2.986 6.600E-06 0.17 1.610E-03 
 30 1.212E-08 9.425E-04 1.611 1.996E-08 2.370E-04 2.652 6.700E-06 0.14 1.940E-03 
 31 1.191E-08 1.025E-03 1.583 2.175E-08 2.370E-04 2.890 5.900E-06 0.17 1.670E-03 
 38 1.140E-08 1.105E-03 1.515 2.175E-08 2.370E-04 2.891 5.300E-06 0.16 2.150E-03 
 x� 1.138E-08 1.033E-03 1.512 
      
 x�± 4.800E-10 7.687E-05 0.064 
      
Tab.6.21: 2-component fit for calculating ACTH response to 10nM CRH (22 h) after 136 h 
  
Fig. 6.17: Concdiff-plot of 2-component fit to 10nM CRH (22 h) after 136 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 5 1.116E-08 8.865E-04 1.483 1.793E-08 2.140E-04 2.382 4.500E-06 0.17 2.240E-03 
 6 1.082E-08 1.164E-03 1.438 1.769E-08 2.140E-04 2.351 8.600E-06 0.16 1.770E-03 
 7 1.006E-08 1.054E-03 1.337 1.811E-08 2.140E-04 2.406 4.200E-06 0.2 1.680E-03 
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 10 1.000E-08 1.084E-03 1.330 1.861E-08 2.140E-04 2.473 3.800E-06 0.19 2.200E-03 
 11 1.129E-08 1.007E-03 1.500 1.771E-08 2.140E-04 2.353 6.800E-06 0.18 2.650E-03 
 13 1.072E-08 9.169E-04 1.424 1.782E-08 2.140E-04 2.368 5.400E-06 0.15 2.010E-03 
 16 1.003E-08 1.099E-03 1.332 1.867E-08 2.140E-04 2.482 5.900E-06 0.14 1.600E-03 
 17 1.126E-08 9.278E-04 1.496 1.806E-08 2.140E-04 2.400 5.600E-06 0.16 2.550E-03 
 19 1.141E-08 8.735E-04 1.517 1.780E-08 2.140E-04 2.366 6.100E-06 0.16 1.620E-03 
 21 1.119E-08 1.032E-03 1.487 1.715E-08 2.140E-04 2.279 5.500E-06 0.18 2.370E-03 
 22 9.423E-09 1.029E-03 1.252 1.994E-08 2.140E-04 2.649 5.100E-06 0.16 2.160E-03 
 27 9.976E-09 9.782E-04 1.326 1.971E-08 2.140E-04 2.620 3.700E-06 0.2 3.140E-03 
 36 1.025E-08 1.187E-03 1.362 1.927E-08 2.140E-04 2.561 5.700E-06 0.14 2.250E-03 
 x� 1.055E-08 1.013E-03 1.401 
      
 x�± 5.758E-10 8.017E-05 0.076 
      
Tab.6.22: 2-component fit for calculating ACTH response to 5nM CRH (22 h) after 114 h 
  
Fig. 6.18: Concdiff-plot of 2-component fit to 5nM CRH (22 h) after 114 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 3 1.166E-08 9.757E-04 1.549 1.785E-08 2.140E-04 2.372 8.300E-06 0.18 1.70E-03 
 4 1.130E-08 9.769E-04 1.502 1.765E-08 2.140E-04 2.346 7.400E-06 0.16 1.68E-03 
 9 1.019E-08 1.135E-03 1.354 1.782E-08 2.140E-04 2.368 4.900E-06 0.17 1.77E-03 
 11 1.053E-08 9.105E-04 1.399 1.811E-08 2.140E-04 2.407 6.000E-06 0.17 2.51E-03 
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 21 9.308E-09 1.084E-03 1.237 1.843E-08 2.140E-04 2.449 3.700E-06 0.18 3.37E-03 
 24 1.029E-08 1.017E-03 1.367 1.774E-08 2.140E-04 2.358 8.100E-06 0.16 1.99E-03 
 25 1.165E-08 8.731E-04 1.549 1.717E-08 2.140E-04 2.281 7.200E-06 0.16 1.78E-03 
 35 1.116E-08 8.477E-04 1.484 1.860E-08 2.140E-04 2.471 6.000E-06 0.17 1.74E-03 
 37 1.109E-08 9.920E-04 1.473 1.769E-08 2.140E-04 2.351 8.400E-06 0.16 1.87E-03 
 39 9.824E-09 9.266E-04 1.305 1.841E-08 2.140E-04 2.447 4.800E-06 0.18 3.84E-03 
 x� 1.063E-08 9.954E-04 1.413 
      
 x� ± 6.701E-10 8.461E-05 0.089 
      
Tab.6.23: 2-component fit for calculating ACTH response to 10nM CRH (22 h) after 114 h 
  
Fig. 6.19: Concdiff-plot of 2-component fit to 10nM CRH (22 h) after 114 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 3 9.141E-09 1.403E-03 1.215 2.000E-08 2.140E-04 2.658 3.800E-06 0.14 2.640E-03 
 4 1.088E-08 9.243E-04 1.446 1.777E-08 2.140E-04 2.362 4.500E-06 0.17 2.500E-03 
 5 1.007E-08 1.105E-03 1.338 1.875E-08 2.140E-04 2.492 5.800E-06 0.15 1.890E-03 
 14 9.368E-09 1.095E-03 1.245 2.060E-08 2.140E-04 2.738 5.400E-06 0.15 2.090E-03 
 15 1.025E-08 1.002E-03 1.362 1.886E-08 2.140E-04 2.506 4.200E-06 0.18 2.140E-03 
 17 1.093E-08 1.021E-03 1.453 1.831E-08 2.140E-04 2.434 4.400E-06 0.17 2.020E-03 
 20 1.050E-08 1.177E-03 1.396 1.902E-08 2.140E-04 2.528 4.400E-06 0.17 2.930E-03 
 21 1.079E-08 1.290E-03 1.434 1.829E-08 2.140E-04 2.431 6.600E-06 0.14 2.440E-03 
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 24 9.987E-09 1.022E-03 1.327 1.799E-08 2.140E-04 2.391 4.200E-06 0.17 2.240E-03 
 27 9.444E-09 1.195E-03 1.255 1.907E-08 2.140E-04 2.534 4.500E-06 0.15 1.770E-03 
 29 1.135E-08 1.013E-03 1.508 1.780E-08 2.140E-04 2.366 7.300E-06 0.15 1.900E-03 
 31 9.183E-09 1.177E-03 1.220 1.983E-08 2.140E-04 2.635 5.600E-06 0.14 1.860E-03 
 32 1.105E-08 1.179E-03 1.468 1.795E-08 2.140E-04 2.385 5.500E-06 0.15 2.010E-03 
 34 1.034E-08 9.087E-04 1.373 1.915E-08 2.140E-04 2.545 5.100E-06 0.17 2.370E-03 
 37 9.438E-09 1.352E-03 1.254 2.004E-08 2.140E-04 2.663 7.600E-06 0.13 2.200E-03 
 39 9.981E-09 1.333E-03 1.326 1.859E-08 2.140E-04 2.470 6.200E-06 0.17 1.830E-03 
 x� 1.016E-08 1.154E-03 1.350 
      
 x�± 5.685E-10 1.346E-04 0.076 
      
Tab.6.24: 2-component fit for calculating ACTH response to 36nM CRH (22 h) after 114 h 
  
Fig. 6.20: Concdiff-plot of 2-component fit to 36nM CRH (22 h) after 114 h 
 
 2fit c2 t2 p2 c1 t1 p1 tauT Triplet chi² 






 1 9.823E-09 1.088E-03 1.305 1.987E-08 2.140E-04 2.641 4.300E-06 0.17 1.590E-03 
 2 1.030E-08 1.149E-03 1.369 1.930E-08 2.140E-04 2.564 6.200E-06 0.17 1.560E-03 
 3 8.729E-09 1.107E-03 1.160 1.937E-08 2.140E-04 2.574 4.400E-06 0.17 1.870E-03 
 5 9.222E-09 1.139E-03 1.225 1.836E-08 2.140E-04 2.441 3.900E-06 0.18 2.730E-03 
 6 1.034E-08 1.150E-03 1.375 1.735E-08 2.140E-04 2.305 6.400E-06 0.15 1.960E-03 
 13 8.777E-09 1.095E-03 1.166 1.849E-08 2.140E-04 2.457 4.300E-06 0.17 1.920E-03 
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 17 9.174E-09 1.038E-03 1.219 1.886E-08 2.140E-04 2.507 4.100E-06 0.18 2.610E-03 
 18 8.349E-09 1.277E-03 1.109 2.027E-08 2.140E-04 2.693 4.100E-06 0.18 1.750E-03 
 19 1.203E-08 8.636E-04 1.598 1.702E-08 2.140E-04 2.261 7.700E-06 0.15 1.590E-03 
 20 8.078E-09 1.328E-03 1.073 1.942E-08 2.140E-04 2.581 3.300E-06 0.18 2.340E-03 
 21 1.167E-08 8.000E-04 1.550 1.673E-08 2.140E-04 2.223 6.200E-06 0.16 2.120E-03 
 24 9.977E-09 1.006E-03 1.326 1.781E-08 2.140E-04 2.366 7.400E-06 0.14 2.160E-03 
 26 8.726E-09 1.316E-03 1.160 1.960E-08 2.140E-04 2.605 3.200E-06 0.2 2.510E-03 
 27 9.253E-09 1.089E-03 1.230 1.897E-08 2.140E-04 2.522 5.800E-06 0.16 2.040E-03 
 28 1.048E-08 8.882E-04 1.392 1.916E-08 2.140E-04 2.547 3.300E-06 0.21 2.670E-03 
 29 1.067E-08 9.263E-04 1.418 1.745E-08 2.140E-04 2.319 6.500E-06 0.16 2.030E-03 
 31 8.657E-09 1.272E-03 1.150 1.953E-08 2.140E-04 2.595 4.000E-06 0.2 2.020E-03 
 33 9.765E-09 1.015E-03 1.298 1.870E-08 2.140E-04 2.485 6.400E-06 0.15 2.270E-03 
 36 9.668E-09 1.187E-03 1.285 1.898E-08 2.140E-04 2.523 4.900E-06 0.17 3.010E-03 
 37 8.074E-09 1.507E-03 1.073 1.847E-08 2.140E-04 2.454 3.200E-06 0.18 2.180E-03 
 38 1.113E-08 8.494E-04 1.479 1.670E-08 2.140E-04 2.220 4.200E-06 0.19 2.690E-03 
 x� 9.665E-09 1.091E-03 1.284 
      
 x�± 8.739E-10 1.386E-04 0.116 
      
Tab.6.25: 2-component fit for calculating ACTH response to 54nM CRH (22 h) after 114 h 
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ACTH adrenocorticotropic hormone, corticotrophin 
Ar argon 
ATCC American Type Culture Collection 
AtT-20 mouse pituitary tumor cell line 
c concentration 
CH constant domain of the heavy immunoglubulin chain 
CL constant domain of the light immunoglobulin chain 
C-term. carboxyl terminal 
CF correction factor 
CNS central nervous system 
CRH corticotropin releasing hormone 
°C degree Celsius 
d distance, optical path length 
DMEM Dulbecco’s Modified Eagle’s Medium 
Da Dalton 
e.g. exempli gratia, for example 
ELISA Enzyme-linked Immunosorbent Assay 
Em emission 
Ex extinction 
et al. et alii, and others 
ε extinction coefficient [M-1cm-1] 
FBS fetal bovine serum 
FCS Fluorescence Correlation Spectroscopy 
Fig. figure 
FSH follicle-stimulating hormone 
g gram 
xg n times gravity 
G (τ) autocorrelation function 
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GH growth hormone, somatotropin 
h hour 
HAT hypoxanthine and thymidine 
HPA hypothalamic-pituitary-adrenal 
I intensity of the absorbed light 
I0 intensity of the initial light beam 
IgG immunoglobulin G  
k- kilo [103] 
l litre 
LAF1 mouse cell line 
LH luteinizing hormone 
μ- micro [10-6] 
m metre 
m- milli [10-3] 
min minutes 
M molarity [mol l-1] 
MW molecular weight 
n- nano [10-9] 
NHS N-hydroxysuccinimide 
N-term. amino terminal 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
POMC proopiomelanocortin 
rER rough endoplasmatic reticulum 
rcf relative centrifugal force 
rpm revolutions per minute, centrifuge rotor speed 
s second 
Tab. table 
TSH thyroid-stimulating hormone, thyrotropin 
V volume 
VH variable domain of the heavy immunoglubulin chain 
VL variable domain of the light  immunoglubulin chain 
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11 Synopsis 
Through important instrumental improvements in the last decades Fluorescence 
Correlation Spectroscopy (FCS) has become a powerful tool for studying supramolecular 
associations, DNA hybridization reactions, etc. However, monitoring and quantifying the 
real time release of a protein in a cellular reaction network by means of FCS opens a 
fundamentally new application of FCS, e.g. in the diagnostic field of medical science, and 
was the aim of our study. For this purpose the HPA axis network, which plays a key role in 
the endocrine system of humans, was chosen as a model for our studies. In support of 
this idea the stimulatory effect of CRH on corticotrophin (ACTH) release from adherent 
AtT-20 pituitaries was analysed. Following the idea of ELISA, a FCS Immunoassay was 
established for detecting ACTH molecules in solution. In vitro real-time release of ACTH 
into the extracellular space in the stationary phase has shown that CRH-induced 
stimulation of ACTH secretion run in two phases, an activation of a non-genomic 
pathway, appearing immediately in a few seconds and minutes after CRH binding to its 
membrane receptor, and a genomic one, requiring a longer exposure time of CRH. The 
latter, long-term effect is known to involve an increase in ACTH via the translation of the 
POMC mRNA, whereas the rapid exocytotic release within seconds and minutes of time is 
ascribed to a reservoir of ACTH vesicles, already existing directly beneath the cell surface 
from previous ACTH synthesis. These observations are consistent with previous reports 
showing the glucocorticoid-induced inhibition of ACTH secretion and thus indicating 
similar pathways for stimulating and inhibiting factors of ACTH secretion.  
The obtained results and the conclusions that could be made demonstrated the single 
molecule sensitivity of this solution based technique. We have recently shown that FCS is 
a powerful spectroscopic tool for detecting even smallest amounts of molecules (in the 
nM and pM range) at a dynamic level and pointed out the advantages of FCS: quicker, 
more cost-efficient, and more sensitive than commercial fluorescent ELISAs.   
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12 Synopsis (in German) 
Herausragende technische Errungenschaften der letzten Jahrzehnte machten Fluoreszenz 
Korrelations Spektroskopie (FCS) zu einer immer wichtigeren Analysetechnik für die 
Untersuchung supramolekularer Assoziationen, DNS Hybridisierungen, etc. Gerade die 
Sekretionsrate eines Proteins in einem zentralen Netzwerksystem des menschlichen 
Körpers live zu verfolgen, war Ziel dieser Arbeit und öffnet einen neuen 
Anwendungsbereich für FCS, beispielsweise in der medizinischen Diagnostik zur Detektion 
spezieller Tumor-Marker. Als zentrales Netzwerksystem wurde für diese Arbeit die 
Hypothalamus-Hypophyse-Nebennieren (HPA) Achse ausgewählt, der eine Schlüsselrolle 
im endokrinen Kreislaufsystem bzw. bei endokrinen Erkrankungen des Menschen 
zukommt. Es wurde der stressinduzierende, stimulierende Effekt von CRH auf die 
Corticotropin (ACTH) Abgabe von AtT-20 Hypophysenzellen analysiert. Mit einer eigens 
entwickelten und auf dem ELISA Prinzip basierten Methode, dem FCS Immunoassay,  
konnten mit extremer Genauigkeit ACTH Moleküle in einer Suspension detektiert werden. 
Die ACTH Ausstoßrate in der stationären Phase in vitro  wurde in Echtzeit verfolgt und 
zeigte, dass die CRH-induzierte ACTH Sekretion in 2 Phasen verläuft: der Aktivierung eines 
non-genomischen Signalweges, welcher innerhalb von Sekunden bis Minuten nach 
Bindung des CRH Moleküls an dessen Membranrezeptor ausgelöst wird, und dem 
genomischen Weg, welcher wahrscheinlich erst nach Stunden zur ACTH Sekretion führt. 
Letzterer führt jedoch zu einer dauerhaften Erhöhung des ACTH Levels durch Translation 
der  POMC mRNA, während die schnelle Exozytose von ACTH in den ersten Sekunden und 
Minuten auf ein sich direkt unter der Zellmembran befindliches Reservoir an ACTH-
Vesikel früherer ACTH Synthesen zurückzuführen ist. Diese Beobachtungen bestätigen 
frühere Studien, die eine durch Glucocortciode hervorgerufene Hemmung der ACTH 
Sekretion zeigen und man daher beim ACTH Ausstoß von ähnlichen Signalwegen für 
stimulierende und inhibierende Faktoren ausgehen kann.  
Die erhaltenen Resultate und die daraus abgeleiteten Aussagen zeigen die Sensitivität 
dieser Technik auf, die sogar kleinste Mengen an Molekülen (im nM- bis pM-Bereich) in 
einer Lösung nachweisen kann. FCS ist schneller, kostengünstiger und sensitiver als 
vergleichbare Fluoreszenz-ELISAs und stellt somit eine ernstzunehmende Alternative dar.  
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